<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0402244833
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VALCYTE 450MG FILM - COATED TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Valganciclovir
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        450
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3791.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PATHEON INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PATHEON INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CHEPLAPHARM Arzneimittel GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AB14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Valcyte belongs to a group of medicines, which work directly to prevent the growth of viruses. In the body the active ingredient in the tablets, valganciclovir, is changed into ganciclovir. Ganciclovir prevents a virus called cytomegalovirus (CMV) from multiplying and invading healthy cells. In patients with a weakened immune system, CMV can cause an infection in the body&rsquo;s organs. This can be life threatening.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte is used:</strong></p><p dir="ltr"><strong>∙ for the treatment of CMV-infections of the retina of the eye in adult patients with acquired immunodeficiency syndrome (AIDS). CMV-infection of the retina of the eye can cause vision problems and even blindness.</strong></p><p dir="ltr"><strong>∙ to prevent CMV-infections in adults and children who are not infected with CMV and who have received an organ transplant from somebody who was infected by CMV.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Valcyte:</strong></p><p dir="ltr"><strong>∙ if you are allergic to valganciclovir, ganciclovir or any of the other ingredients of this medicine (listed in section 6).</strong></p><p dir="ltr"><strong>∙ if you are breast-feeding.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Warnings and precautions:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Talk to your doctor or pharmacist before taking Valcyte:</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>if you are allergic to aciclovir, penciclovir, valaciclovir or famciclovir. These are other medicines used for viral infections.</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>Take special care with Valcyte</strong></p><p dir="ltr"><strong>∙ if you have low numbers of white blood cells, red blood cells or platelets (small cells involved in blood clotting) in your blood. Your doctor will carry out blood tests before you start taking Valcyte tablets and more tests will be done while you are taking the tablets.</strong></p><p dir="ltr"><strong>∙ if you are having radiotherapy or haemodialysis</strong></p><p dir="ltr"><strong>∙ if you have a problem with your kidneys. Your doctor may need to prescribe a reduced dose for you and may need to check your blood frequently during treatment.</strong></p><p dir="ltr"><strong>∙ if you are currently taking ganciclovir capsules and your doctor wants you to switch to Valcyte tablets. It is important that you do not take more than the number of tablets prescribed by your doctor or you could risk an overdose.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other medicines and Valcyte</strong></p><p dir="ltr"><strong>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you take other medicines at the same time as taking Valcyte the combination could affect the amount of drug that gets into your blood stream or could cause harmful effects. Tell your doctor if you are already taking medicines that contain any of the following:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>∙ imipenem-cilastatin (an antibiotic). Taking this with Valcyte can cause convulsions (fits)</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>zidovudine, didanosine, lamivudine, stavudine, tenofovir, abacavir, emtricitabine or similar kinds of drugs used to treat AIDS</strong></p></li><li dir="ltr"><p dir="ltr"><strong>adefovir or any other medicines used to treat Hepatitis B</strong></p></li></ul><p dir="ltr"><strong>∙ probenecid (a medicine against gout). Taking probenecid and Valcyte at the same time could increase the amount of ganciclovir in your blood</strong></p><p dir="ltr"><strong>∙ mycophenolate mofetil, ciclosporin or tacrolimus (used after transplantations)</strong></p><p dir="ltr"><strong>∙ vincristine, vinblastine, doxorubicin, hydoxyurea or similar kinds of drugs to treat cancer</strong></p><p dir="ltr"><strong>∙ trimethoprim, trimethoprim/sulpha combinations and dapsone (antibiotics)</strong></p><p dir="ltr"><strong>∙ pentamidine (drug to treat parasite or lung infections)</strong></p><p dir="ltr"><strong>∙ flucytosine or amphotericin B (anti-fungal agents)</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte with food and drink</strong></p><p dir="ltr"><strong>Valcyte should be taken with food. If you are unable to eat for any reason, you should still take your dose of Valcyte as usual.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy, breast-feeding and fertility</strong></p><p dir="ltr"><strong>You should not take Valcyte if you are pregnant unless your doctor recommends it. If you are pregnant or planning to become pregnant you must tell your doctor. Taking Valcyte when you are pregnant could harm your unborn baby.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>You must not take Valcyte if you are breast-feeding. If your doctor wants you to begin treatment with Valcyte you must stop breast-feeding before you start to take your tablets.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Women of childbearing age must use effective contraception when taking Valcyte and for at least 30 days after treatment has finished.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Men whose partners could become pregnant should use condoms while taking Valcyte and should continue to use condoms for 90 days after treatment has finished.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr"><strong>Do not drive or use any tools or machines if you feel dizzy, tired, shaky or confused while taking this medicine.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Ask your doctor or pharmacist for advice before taking any medicine.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>You have to be careful when handling your tablets. Do not break or crush them. You should swallow them whole and with food whenever possible. If you accidentally touch damaged tablets, wash your hands thoroughly with soap and water. If any powder from the tablets gets in your eyes, rinse your eyes with sterile water or clean water if you do not have sterile water.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>You must stick to the number of tablets as instructed by your doctor to avoid overdose.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte tablets should, whenever possible, be taken with food &ndash; see section 2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adults:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prevention of CMV disease in transplant patients</strong></p><p dir="ltr"><strong>You should start to take this medicine within 10 days of your transplant. The usual dose is two tablets taken ONCE daily. You should continue with this dose for up to 100 days following your transplant. If you have received a kidney transplant, your doctor may advise you to take the tablets for 200 days.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Treatment of active CMV retinitis in AIDS patients (called induction treatment)</strong></p><p dir="ltr"><strong>The usual dose Valcyte is two tablets taken TWICE a day for 21 days (three weeks). Do not take this dose for more than 21 days unless your doctor tells you to, as this may increase your risk of possible side effects.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Longer term treatment to prevent recurrence of active inflammation in AIDS patients with CMV retinitis (called maintenance treatment)</strong></p><p dir="ltr"><strong>The usual dose is two tablets taken ONCE daily. You should try to take the tablets at the same time each day.&nbsp; Your doctor will advise you how long you should continue to take Valcyte. If your retinitis worsens while you are on this dose, your doctor may tell you to repeat the induction treatment (as above) or may decide to give you a different medicine to treat the CMV infection.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly patients</strong></p><p dir="ltr"><strong>Valcyte has not been studied in elderly patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with kidney problems</strong></p><p dir="ltr"><strong>If your kidneys are not working properly, your doctor may instruct you to take fewer tablets each day or only to take your tablets on certain days each week. It is very important that you only take the number of tablets prescribed by your doctor.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with liver problems</strong></p><p dir="ltr"><strong>Valcyte has not been studied in patients with liver problems.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Use in children and adolescents:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prevention of CMV disease in transplant patients</strong></p><p dir="ltr"><strong>Children should start to take this medicine within 10 days of their transplant.&nbsp; The dose given will vary depending on the size of the child and should be taken ONCE daily.&nbsp; Your doctor will decide the most appropriate dose based on your child&rsquo;s height, weight and renal function.&nbsp; You should continue with this dose for up to 100 days. If your child has received a kidney transplant, your doctor may advise you to take the dose for 200 days.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For children who are unable to swallow Valcyte film-coated tables, Valcyte powder for oral solution can be used.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you take more Valcyte than you should</strong></p><p dir="ltr"><strong>Contact your doctor or hospital immediately if you have taken, or think that you have taken, more tablets than you should. Taking too many tablets can cause serious side effects, particularly affecting your blood or kidneys. You may need hospital treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you forget to take Valcyte</strong></p><p dir="ltr"><strong>If you forget to take your tablets take the missed dose as soon as you remember and take the next dose at the usual time. Do not take a double dose to make up for the forgotten tablets.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you stop taking Valcyte</strong></p><p dir="ltr"><strong>You must not stop taking your medicine unless your doctor tells you to.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Like all medicines, this medicine can cause side effects, although not everybody gets them.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Allergic reactions</strong></p><p dir="ltr"><strong>Up to 1 in every 1,000 people may have a sudden and severe allergic reaction to valganciclovir (anaphylactic shock). STOP taking Valcyte and go to the accident and emergency department at your nearest hospital if you experience any of the following:</strong></p><p dir="ltr"><strong>∙ a raised, itchy skin rash (hives)</strong></p><p dir="ltr"><strong>∙ sudden swelling of the throat, face, lips and mouth which may cause difficulty swallowing or breathing</strong></p><p dir="ltr"><strong>∙ sudden swelling of the hands, feet or ankles.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Serious side effects</strong></p><p dir="ltr"><strong>Tell your doctor straight away if you notice any of the following serious side effects &ndash; your doctor may tell you to stop taking Valcyte and you may need urgent medical treatment:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Very common: may affect more than 1 in 10 people</strong></p><p dir="ltr"><strong>∙ low white blood cell counts &ndash; with signs of infection such as sore throat, mouth ulcers or a fever&nbsp;</strong></p><p dir="ltr"><strong>∙ low red blood cell counts &ndash; signs include feeling short of breath or tired, palpitations or pale skin</strong></p><p dir="ltr"><strong>Common: may affect up to 1 in 10 people</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>blood infection (sepsis) &ndash; signs include fever, chills, palpitations, confusion and slurred speech</strong></p></li><li dir="ltr"><p dir="ltr"><strong>low level of platelets &ndash; signs include bleeding or bruising more easily than usual, blood in urine or stools or bleeding from gums, the bleeding could be severe</strong></p></li><li dir="ltr"><p dir="ltr"><strong>severely low blood cell count</strong></p></li><li dir="ltr"><p dir="ltr"><strong>pancreatitis &ndash; signs are severe stomach pain which spreads into your back</strong></p></li><li dir="ltr"><p dir="ltr"><strong>fits</strong></p></li></ul><p dir="ltr"><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p dir="ltr"><strong>∙ failure of the bone marrow to produce blood cells</strong></p><p dir="ltr"><strong>∙ hallucinations &ndash; hearing or seeing things that are not real&nbsp;</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>abnormal thoughts or feelings, losing contact with reality</strong></p></li><li dir="ltr"><p dir="ltr"><strong>failure of kidney function</strong></p></li></ul><p><br />&nbsp;</p><p dir="ltr"><strong>The side effects that have occurred during treatment with valganciclovir or ganciclovir are given below.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other side effects</strong></p><p dir="ltr"><strong>Tell your doctor, pharmacist or nurse if you notice any of the following side effects:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Very common: may affect more than 1 in 10 people</strong></p><p dir="ltr"><strong>∙ thrush and oral thrush</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>upper respiratory tract infection (e.g. sinusitis, tonsillitis)</strong></p></li><li dir="ltr"><p dir="ltr"><strong>loss of appetite</strong></p></li><li dir="ltr"><p dir="ltr"><strong>headache</strong></p></li><li dir="ltr"><p dir="ltr"><strong>cough</strong></p></li></ul><p dir="ltr"><strong>∙ feeling short of breath</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>diarrhoea</strong></p></li><li dir="ltr"><p dir="ltr"><strong>feeling or being sick</strong></p></li><li dir="ltr"><p dir="ltr"><strong>abdominal pain</strong></p></li><li dir="ltr"><p dir="ltr"><strong>eczema</strong></p></li><li dir="ltr"><p dir="ltr"><strong>feeling tired</strong></p></li><li dir="ltr"><p dir="ltr"><strong>fever.</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>Common: may affect up to 1 in 10 people</strong></p><p dir="ltr"><strong>∙ influenza</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>urine infection &ndash; signs include fever, passing urine more often, pain when passing urine</strong></p></li><li dir="ltr"><p dir="ltr"><strong>infection of the skin and the tissues under the skin</strong></p></li><li dir="ltr"><p dir="ltr"><strong>mild allergic reaction &ndash; the signs may include red, itchy skin</strong></p></li><li dir="ltr"><p dir="ltr"><strong>weight loss</strong></p></li><li dir="ltr"><p dir="ltr"><strong>feeling depressed, anxious or confused</strong></p></li></ul><p dir="ltr"><strong>∙ trouble sleeping</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>hands or feet feeling weak or numb, which may affect your balance</strong></p></li><li dir="ltr"><p dir="ltr"><strong>changes to your sense of touch, tingling, tickling, pricking or burning feeling</strong></p></li><li dir="ltr"><p dir="ltr"><strong>changes to the way things taste</strong></p></li><li dir="ltr"><p dir="ltr"><strong>chills</strong></p></li><li dir="ltr"><p dir="ltr"><strong>eye inflammation (conjunctivitis), eye pain or sight problems</strong></p></li><li dir="ltr"><p dir="ltr"><strong>ear pain</strong></p></li><li dir="ltr"><p dir="ltr"><strong>low blood pressure, which may make you feel dizzy or faint</strong></p></li><li dir="ltr"><p dir="ltr"><strong>problems swallowing</strong></p></li><li dir="ltr"><p dir="ltr"><strong>constipation, wind, indigestion, stomach pain, swelling of the abdomen</strong></p></li><li dir="ltr"><p dir="ltr"><strong>mouth ulcers</strong></p></li><li dir="ltr"><p dir="ltr"><strong>abnormal results of liver and kidney laboratory tests</strong></p></li></ul><p dir="ltr"><strong>∙ night sweats</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>itching, rash</strong></p></li><li dir="ltr"><p dir="ltr"><strong>hair loss</strong></p></li><li dir="ltr"><p dir="ltr"><strong>back pain, muscle or joint pain, muscle spasms</strong></p></li><li dir="ltr"><p dir="ltr"><strong>feeling dizzy, weak or generally unwell</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p dir="ltr"><strong>∙ feeling agitated</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>tremor, shaking</strong></p></li></ul><p dir="ltr"><strong>∙ deafness</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>uneven heartbeat</strong></p></li></ul><p dir="ltr"><strong>∙ hives, dry skin</strong></p><p dir="ltr"><strong>∙ blood in urine</strong></p><ul><li dir="ltr"><p dir="ltr"><strong>infertility in men &ndash; see &lsquo;Fertility&rsquo; section</strong></p></li></ul><ul><li dir="ltr"><p dir="ltr"><strong>chest pain</strong></p></li></ul><p>&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Separation of the inner lining of the eye (detached retina) has only happened in AIDS patients treated with Valcyte for CMV infection.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Additional side effects in children and adolescents</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The side effects reported in children and adolescents are similar to the side effects reported for adults.&nbsp;&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of side effects</strong></p><p dir="ltr"><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Keep this medicine out of the sight and reach of children.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Do not use this medicine after the expiry date, which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>This medicine does not require any special storage conditions.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Valcyte contains&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The active substance is 450&nbsp;mg of valganciclovir, present as 496.3&nbsp;mg of valganciclovir hydrochloride.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The other ingredients (excipients) in the tablet are Povidone K30, crospovidone, microcrystalline cellulose and stearic acid. The ingredients in the film-coat are hypromellose, titanium dioxide (E171), macrogol 400, red iron oxide (E172) and polysorbate 80.&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Valcyte tablets are pink oval film-coated tablets marked “VGC” on one side and “450” on the other side.

They are packed in bottles containing 60 film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>F. Hoffmann-La Roche Ltd,</strong></p><p dir="ltr"><strong>Grenzacherstrasse 124,</strong></p><p dir="ltr"><strong>CH-4070 Basel,</strong></p><p dir="ltr"><strong>Switzerland.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2018.

To report any side effect(s):
Saudi Arabia:
The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
SFDA call center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc

Other GCC States:
Please contact the relevant competent authority.

Council of Arab Health Ministers
This is a Medicament
Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you. 
Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament. 
The doctor and the pharmacist are the experts in medicines, their benefits and risks. 
Do not by yourself interrupt the period of treatment prescribed for you. 
Do not repeat the same prescription without consulting your doctor. 
Keep all medicaments out of reach of children. 

Council of Arab Health Ministers
Union of Arab Pharmacists



            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="rtl"><strong>ينتمي فالسيت لمجموعة دوائية تعمل مباشرة لتمنع نمو الفيروسات. داخل الجسم، تتحول المادة الفعالة الموجود في القرص (فالغانسيكلوفير) إلى مادة (غانسيكلوفير) والتي بدورها تمنع فيروس يطلق عليه الفيروس المضخم للخلايا (CMV) من التكاثر وإصابة الخلايا السليمة. يمكن أن يتسبب الفيروس المضخم للخلايا (CMV) في حدوث عدوى (التهاب) في أعضاء الجسم لدى المرضى الذين يعانون من ضعف الجهاز المناعي، مما قد يشكل خطراً يهدد حياتهم.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>دواعي استعمال فالسيت:</strong></p><p dir="rtl"><strong>&nbsp;يستخدم فالسيت في:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>علاج عدوى الفيروس المضخم للخلايا في شبكية العين لدى المرضى البالغين المصابين بمتلازمة نقص المناعة المكتسبة (الإيدز). قد تتسبب عدوى شبكية العين بالفيروس المضخم للخلايا (CMV) في مشاكل في الرؤية قد تصل إلى فقدان البصر.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>منع العدوى بالفيروس المضخم للخلايا (CMV) لدى البالغين والأطفال غير المصابين بالفيروس نفسه والذين خضعوا مؤخرًا لزراعة عضو من متبرع مصاب بفيروس (CMV).</strong></p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>لا تتعاطى فالسيت في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إن كنت تعاني من الحساسية تجاه فالغانسيكلوفير أو غانسيكلوفير أو أي من المكونات الأخرى لهذا الدواء (مذكورة في الجزء 6).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أثناء فترة الرضاعة الطبيعية.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>التحذيرات والاحتياطات:</strong></p><p dir="rtl"><strong>تحدث مع طبيبك أو الصيدلي قبل تعاطي فالسيت في الحالات التالية:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إن كنت تعاني من حساسية تجاه أسيكلوفير أو فالاسيكلوفير أو فامسيكلوفير، وهي أدوية أخرى تستخدم لعلاج الالتهابات الفيروسية.</strong></p></li></ul><p dir="rtl"><strong>توخى الحذر عند تعاطي فالسيت:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>إن كنت تعاني نقصًا في عدد كريات الدم البيضاء أو الحمراء أو الصفائح (الخلايا الدموية الصغيرة التي تلعب دوراً في عملية تجلط الدم). سيقوم طبيبك بإجراء فحوصات للدم قبل أن يصف لك أقراص فالسيت، وسيتم إجراء المزيد من الفحوصات أثناء تعاطيك الأقراص.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إن كنت تتلقى علاجًا إشعاعياً أو تخضع لغسيل الكلى.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إن كنت تعاني من مشاكل في الكلى، فقد يحتاج طبيبك أن يصف لك جرعة مخفضة، وقد تحتاج لإجراء فحصٍ للدم بشكل متكرر أثناء العلاج.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إن كنت تتعاطي كبسولات غانسيكلوفير في الوقت الحالي وقد طلب منك طبيبك استبدالها بأقراص فالسيت. من المهم ألا تتعاطي عددًا أكبر من الأقراص الموصوفة لك من قبل طبيبك، وإلا فقد تتعرض لخطر الجرعة المفرطة.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>تفاعل فالسيت مع الأدوية الأخرى:</strong></p><p dir="rtl"><strong>أخبر طبيبك أو الصيدلي إن كنت تتعاطى، أو تعاطيت مؤخرًا، أو قد تتعاطى أية أدوية أخرى، بما في ذلك الأدوية التي يمكن الحصول عليها بدون وصفة طبية.</strong></p><p dir="rtl"><strong>إذا كنت تتعاطى أدوية أخرى أثناء تعاطي فالسيت، فإن هذا قد يؤثر على كمية الدواء الذي يصل للدم أو قد يؤدي لنتائج ضارة. اطلع طبيبك إن كنت تتعاطى بالفعل أية أدوية تحتوي على أي مما يلي:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>أميبينيم سيلاستاتين (مضاد حيوي). تعاطي هذا الدواء مع فالسيت قد يؤدي إلى الإصابة بتشنجات.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>زيدوفودين أو دايدانوسين أو لاميفودين أو ستافودين أو تينوفوفير أو اباكافير أو امتريسيتابين أو أي نوع مشابه من الأدوية المستخدمة لعلاج الإيدز.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اديفوفير أو أي دواء أخر يستخدم لعلاج الالتهاب الكبدي الفيروسي ب.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>بروبنسيد (دواء لعلاج النقرس). تعاطي بروبنسيد أثناء تعاطي فالسيت قد يزيد من كمية مادة غانسيكلوفير في دمك.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ميكوفينوليت موفيتيل أو سيكلوسبورين أو تاكروليمس (المستخدمة بعد عمليات زراعة الأعضاء).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فينكريستين أو فينبلاستين أو دوكسوروبيسين أو هيدروكسي يوريا أو أي أنواع مشابهة أخرى من أدوية علاج السرطان.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تريميثوبريم أو تريميثوبريم / مركبات السلفا ودابسون (مضادات حيوية)</strong></p></li><li dir="rtl"><p dir="rtl"><strong>بينتاميدين (عقار يستخدم لعلاج الطفيليات أو الالتهابات الرئوية).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فلوسيتوزين أو أمفوتيريسين ب (عقار مضاد للفطريات).</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>تفاعل فالسيت مع الأطعمة والمشروبات:</strong></p><p dir="rtl"><strong>يجب تعاطي فالسيت مع الطعام، إن كنت غير قادرٍ على تناول الطعام لأي سبب من الأسباب، عليك الاستمرار في تعاطي جرعتك من فالسيت كالمعتاد.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الحمل والرضاعة والخصوبة:</strong></p><p dir="rtl"><strong>لا ينبغي أن تتعاطي فالسيت إن كنت حاملًا ما لم يوص طبيبك بذلك.&nbsp;</strong></p><p dir="rtl"><strong>إن كنت حاملًا أو تخططين للحمل، عليك إطلاع طبيبك على هذا الأمر. حيث من الممكن أن يؤذي فالسيت جنينك في حالة تناوله أثناء الحمل.</strong></p><p dir="rtl"><strong>لا ينبغي تناول فالسيت أثناء فترة الرضاعة الطبيعية، في حال رغبة طبيبك بدء العلاج باستخدام فالسيت، عليك التوقف عن الرضاعة قبل البدء في تعاطي الأقراص.</strong></p><p dir="rtl"><strong>على السيدات في سن الإنجاب استخدام وسائل فعالة لمنع الحمل أثناء تعاطي فالسيت ولمدة لاتقل عن 30 يوم بعد انتهاء العلاج.</strong></p><p dir="rtl"><strong>على الرجال - الذين يمكن لزوجاتهم الحمل- استعمال الواقيات الذكرية أثناء تعاطي فالسيت، وعليهم الاستمرار في استخدامها لمدة 90 يوم بعد انتهاء العلاج.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>القيادة وتشغيل الآلات:</strong></p><p dir="rtl"><strong>لا تقد أو تستخدم أية آلات أو معدات إن كنت تشعر بالدوار أو التعب أو عدم الاتزان أو الارتباك أثناء تعاطي هذا الدواء.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>استشر طبيبك أو الصيدلي قبل تعاطي أي دواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>تناول هذا الدواء دائماً وفق الجرعة المحددة من قبل طبيبك أو الصيدلي. ارجع للطبيب أو الصيدلي في حال لم تكن متأكدًا.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>عليك توخي الحذر عند التعامل مع هذه الأقراص. لا تكسرها أو تطحنها. عليك ابتلاعها بالكامل مع الطعام متى أمكن. إن لامست قرصًا مكسورًا عن طريق الخطأ، اغسل يديك باستخدام الماء والصابون. وإذا دخل المسحوق الموجود في القرص إلى عينيك، اغسلها بماء معقم أو ماء نظيف إن لم يكن لديك ماء معقم.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>عليك الالتزام بتناول عدد الأقراص التي أوصى بها طبيبك لتجنب تعاطي جرعة مفرطة.</strong></p><p dir="rtl"><strong>يجب تعاطي أقراص فالسيت مع الطعام كلما كان ذلك ممكنًا &ndash; أنظر الجزء 2.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>البالغين:</strong></p><p dir="rtl"><strong>للوقاية من مرض الفيروس المضخم للخلايا لدى المرضى الخاضعين لعمليات زراعة الأعضاء:</strong></p><p dir="rtl"><strong>عليك البدء في تعاطي هذا الدواء خلال 10 أيام من إجراء جراحة الزرع. الجرعة المعتادة هي قرصين مرة واحدة يوميًا. عليك الاستمرار على هذه الجرعة لمدة تصل إلى 100 يوم بعد الجراحة. وإن كنت قد أجريت زرعًا للكلية، قد يطلب منك طبيبك أن تتناول الأقراص لمدة 200 يوم.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>علاج عدوى التهاب الشبكية النشط بالفيروس المضخم للخلايا لدى مرضى الإيدز (يطلق عليه العلاج المبدئي):</strong></p><p dir="rtl"><strong>الجرعة المعتادة من فالسيت هي قرصين تؤخذ مرتين يوميًا لمدة 21 يوم (ثلاثة أسابيع). لا تتعاطى هذا الدواء لمدة تزيد عن 21 يوم ما لم يوص طبيبك بذلك، حيث قد يزيد ذلك من خطر إصابتك بآثار جانبية محتملة.</strong></p><p><br /><br />&nbsp;</p><p dir="rtl"><strong>العلاج لفترة أطول لتجنب تكرار الالتهابات النشطة لدى مرضى الإيدز فيما يتعلق بالتهاب الشبكية (يطلق عليه العلاج الوقائي):</strong></p><p dir="rtl"><strong>الجرعة المعتادة هي قرصين مرة واحدة يومياً. عليك محاولة تناول الأقراص في الوقت نفسه يومياً. سيحدد طبيبك المدة التي يجب عليك الالتزام خلالها بتناول أقراص فالسيت. إن ساءت حالة التهاب الشبكية لديك أثناء تعاطيك لتلك الجرعة، قد يطلب منك طبيبك تكرار جرعة العلاج المبدئي (كما هو مبين أعلاه)، أو قد يقرر إعطائك دواء مختلف لعلاج عدوى الفيروس المضخم للخلايا لديك.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>المرضى كبار السن:</strong></p><p dir="rtl"><strong>لم تتم دراسة فالسيت على المرضى كبار السن.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>المرضى الذين يعانون من مشاكل الكلى:</strong></p><p dir="rtl"><strong>إن لم تكن كليتاك تعملان بكفاءة، قد يطلب منك طبيبك تعاطي عدد أقل من الأقراص كل يوم، أو تعاطي الأقراص الخاصة بك في أيام معينة في الأسبوع. من المهم للغاية أن تتعاطى عدد الأقراص الذي يحدده طبيبك.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>المرضى الذين يعانون من مشاكل الكبد:</strong></p><p dir="rtl"><strong>لم تتم دراسة فالسيت على المرضى الذين يعانون من مشاكل في الكبد.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الاستخدام مع الأطفال والمراهقين:</strong></p><p dir="rtl"><strong>الوقاية من مرض فيروس تضخم المناعة لدى المرضى الخاضعين لعمليات زراعة الأعضاء:</strong></p><p dir="rtl"><strong>على الأطفال البدء في تعاطي الدواء خلال 10 أيام من إجراء جراحة الزرع. تختلف الجرعة وفقًا لحجم الطفل، ويجب تعاطيها مرة واحدة فقط يوميًا. سيقرر طبيبك الجرعة المناسبة وفقًا لطول ووزن طفلك ووظائف الكلى لديه. عليك الاستمرار على هذه الجرعة لمدة تصل إلى 100 يوم. إن أجرى طفلك جراحة زرع كلية، قد ينصحك طبيبه بجعله يتعاطى الجرعة لمدة 200 يوم.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>للأطفال غير القادرين على بلع أقراص فالسيت المغلفة، يمكن استخدام الشكل الصيدلاني الآخر لفالسيت والذي هو عبارة عن محلول لمسحوق يؤخذ عن طريق الفم.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إن تناولت جرعة زائدة من فالسيت:</strong></p><p dir="rtl"><strong>اتصل بطبيبك أو بالمستشفى فورًا إن كنت قد تعاطيت، أو إن كنت تعتقد إنك قد تعاطيت عدداً زائداً من الأقراص. تناول عدد أكبر من الأقراص قد يتسبب في الإصابة بآثار جانبية، وقد يؤثر بشكل خاص على دمك أو كليتيك. وقد تحتاج لتلقي العلاج في المستشفى.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إن نسيت تناول فالسيت:</strong></p><p dir="rtl"><strong>إن نسيت تناول القرص الخاص بك، عليك تناول القرص فور تذكرك، وتعاطى القرص التالي في موعده المعتاد. لا تتناول جرعة مزدوجة لتعويض القرص الذي نسيته.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إن توقفت عن تعاطي فالسيت:</strong></p><p dir="rtl"><strong>عليك عدم التوقف عن تعاطي الدواء الخاص بك ما لم يخبرك طبيبك بذلك.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>إن كان لديك أية أسئلة إضافية بخصوص استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>كمثل جميع الأدوية، قد يتسبب هذا الدواء في آثار جانبية، إلا أنها ليست بالضرورة أن تصيب الجميع.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الحساسية:</strong></p><p dir="rtl"><strong>قد يعاني شخص واحد من كل 1000 شخص من ردود فعل تحسسية مفاجأة وشديدة تجاه فالغانسيكلوفير (صدمة تحسسية).&nbsp;</strong></p><p dir="rtl"><strong>توقف عن تعاطي فالسيت وتوجه لقسم الحوادث والطوارئ في أقرب مستشفى إن تعرضت لأي مما يلي:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>طفح جلدي نافر ومسبب للحكة (بثور).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تورم مفاجئ في الحلق والوجه والشفتين والفم مما قد يسبب صعوبة في البلع أو التنفس.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تورم مفاجئ في اليدين أو القدمين أو الكاحلين.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>الآثار الجانبية الخطيرة:</strong></p><p dir="rtl"><strong>اخبر طبيبك فوراً إن لاحظت الآثار الجانبية الخطيرة التالية &ndash; قد يطلب منك طبيبك التوقف عن تعاطي فالسيت، وقد تحتاج لمساعدة طبية عاجلة -:</strong></p><p dir="rtl"><strong>شائعة للغاية: قد تصيب أكثر من شخص واحد من بين 10 أشخاص:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>انخفاض عدد كريات الدم البيضاء &ndash; مع أعراض الإصابة بالتهاب مثل ألم الحلق أو قرح الفم أو الحمى.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض عدد كريات الدم الحمراء &ndash; وتشمل الأعراض قصر النفس أو التعب أو تسارع نبضات القلب أو شحوب البشرة.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>شائعة: قد تصيب شخص واحد من بين 10 أشخاص:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>تسمم الدم (عدوى بكتيرية أو فيروسية تصيب الدم) &ndash; الأعراض تشمل الحمى، الشعور بالقشعريرة أو الرجفة، الخفقان، الارتباك، الكلام المتداخل غير الواضح.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض مستوى الصفائح الدموية &ndash; وتشمل الأعراض النزيف أو الإصابة بالكدمات بشكل أسهل من المعتاد أو وجود دم في البول أو البراز أو نزيف اللثة، وقد يكون النزيف شديدًا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض تعداد كريات الدم بشكل حاد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب البنكرياس &ndash; وتشمل الأعراض ألم حاد في المعدة يمتد إلى الظهر.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تشنجات.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>غير شائعة: قد تصيب شخص واحد من بين 100 شخص:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>فشل نخاع العظم في انتاج خلايا الدم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>هلاوس &ndash; سماع أو رؤية أشياء غير حقيقية.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>أفكار أو مشاعر غير طبيعية، فقدان الاتصال بالواقع.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فشل في وظائف الكلى.</strong></p></li></ul><p dir="rtl"><strong>فيما يلي الآثار الجانبية التي تصاحب العلاج باستخدام فالغانسيكلوفير أو غانسيكلوفير:</strong></p><p dir="rtl"><strong>آثار جانبية أخرى:</strong></p><p dir="rtl"><strong>اخبر طبيبك أو الصيدلي أو الممرضة إذا لاحظت أي من الآثار الجانبية التالية:</strong></p><p dir="rtl"><strong>شائعة للغاية: قد تصيب أكثر من شخص واحد من بين 10 أشخاص:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>القلاع والتهاب الفم الفطري.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>عدوى الجهاز التنفسي العلوي (مثل: التهاب الجيوب الأنفية والتهاب اللوزتين).</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فقدان الشهية.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الصداع.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>السعال.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بضيق النفس.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الإسهال.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالإعياء أو الغثيان.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في البطن.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>اكزيما.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالتعب.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الحمى (ارتفاع درجة الحرارة).</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>شائعة: قد تصيب شخص واحد من بين 10 أشخاص:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الانفلونزا.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب مجرى البول &ndash; وتشمل الأعراض الحمى، التبول أكثر من المعتاد، والشعور بألم عند التبول.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهابات الجلد والأنسجة تحت الجلد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>حساسية طفيفة &ndash; وتشمل الأعراض احمرار الجلد والشعور بالحكة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فقدان الوزن.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالاكتئاب أو القلق أو الارتباك.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>مشاكل في النوم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بضعف أو خدر في اليدين أو القدمين، مما قد يؤثر على التوازن.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تغير حاسة اللمس لديك أو الشعور بتنميل أو دغدغة أو وخز أو حرقة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تغير في مذاق الأشياء المعتادة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قشعريرة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>التهاب العيون (التهاب الملتحمة) أو ألم في العين أو مشاكل في الرؤية.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في الأذن.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>انخفاض في ضغط الدم مما قد يُشعرك بالدوار أو الإغماء.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>صعوبة في البلع.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>إمساك أو ريح أو عسر هضم أو ألم أو انتفاخ في البطن.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>قروح الفم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>نتائج غير طبيعية لتحاليل وظائف الكلى أو الكبد.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>تعرق ليلي.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>حكة أو طفح جلدي.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>فقدان الشعر.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في الظهر أو العضلات أو المفاصل أو تشنجات عضلية.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الشعور بالدوار أو الضعف أو الإعياء بوجه عام.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>غير شائعة: قد تصيب شخص واحد من بين 100 شخص:</strong></p><ul><li dir="rtl"><p dir="rtl"><strong>الشعور بالاضطراب.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الرعشة أو الارتجاف.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>الصمم.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ضربات قلب غير منتظمة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>بثور أو جفاف في البشرة.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>دم في البول.</strong></p></li><li dir="rtl"><p dir="rtl"><strong>العقم لدى الرجال &ndash; أنظر قسم &quot;الخصوبة&quot;</strong></p></li><li dir="rtl"><p dir="rtl"><strong>ألم في الصدر.</strong></p></li></ul><p>&nbsp;</p><p dir="rtl"><strong>لوحظ حصول انفصال البطانة الداخلية للعين (انفصال الشبكية) فقط لدى مرضى الإيدز&nbsp; الذين عولجوا من الإصابة بعدوى الفيروس المضخم للخلايا ((CMV باستخدام فالغانسيكلوفير أو غانسيكلوفير.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>آثار جانبية إضافية لدى الأطفال والمراهقين:</strong></p><p dir="rtl"><strong>الآثار الجانبية التي تم التبليغ عنها لدى الأطفال والمراهقين مشابهة للآثار الجانبية التي تعرض لها البالغين.</strong></p><p>&nbsp;</p><p dir="rtl"><strong>الإبلاغ عن الآثار الجانبية:</strong></p><p dir="rtl"><strong>إن تعرضت لأية آثار جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أية آثار جانبية غير مدرجة في هذه النشرة. عن طريق الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>احتفظ بهذا الدواء بعيدًا عن متناول الأطفال.</strong></p><p dir="rtl"><strong>لا تتناول هذا الدواء بعد انتهاء صلاحيته، تاريخ الانتهاء مذكور على العبوة والكرتون بعد كلمة EXP. ويشير تاريخ انتهاء الصلاحية لآخر يوم في ذلك الشهر.</strong></p><p dir="rtl"><strong>لا يحتاج هذا الدواء لشروط تخزين خاصة.</strong></p><p dir="rtl"><strong>لا تتخلص من هذا الدواء عبر مياه الصرف أو في النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستخدمها. ستساعد تلك الإجراءات على حماية البيئة.&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>علام يحتوي فالسيت:</strong></p><p dir="rtl"><strong>المادة الفعالة هي 450 مج من فالغانسيكلوفير متمثلة في 496.3 مج من هيدروكلوريد الفالغانسيكلوفير.</strong></p><p dir="rtl"><strong>المكونات الأخرى (المكونات غير الفعالة) في القرص هي البوفيدون كيه 30، كورسبوفيدون، ميكروكريستالين سليلوز والحامض الدهني. المواد الموجودة في غلاف القرص هي هيدروكسي بروبيل ميثيل سيللوز وثاني أكسيد التيتانيوم (E171)، ماكروغول 400، أكسيد الحديد الأحمر (E172) وبوليسوربات 80.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>ما هو شكل فالسيت وما هي محتويات العبوة:</strong></p><p dir="rtl"><strong>أقراص فالسيت وردية اللون وبيضاوية الشكل وهي أقراص مغلفة تحمل العلامة &ldquo;VGC&rdquo; من جهة و&quot;450&quot; من الجهة الأخرى.</strong></p><p dir="rtl"><strong>وهي معبأة في زجاجات تحتوي على 60 قرص مغلف.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="rtl"><strong>شركة ف. هوفمان لا روش المحدودة</strong></p><p dir="rtl"><strong>142 جرينزاهاشتراس</strong></p><p dir="rtl"><strong>CH &ndash; 4070 بازل</strong></p><p dir="rtl"><strong>سويسرا</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذ النشرة كانت في مايو 2018



للإبلاغ عن الآثار الجانبية:
المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
فاكس: 7662-205-11-966+
او اتصل بالمركز على رقم 20380222-11-966+، داخلي: 2317 – 2356 – 2340.
مركز اتصالات الهيئة العامة للغذاء والدواء: 19999
بريد الكتروني: npc.drug@sfda.gov.sa
الموقع الإلكتروني: www.sfda.gov.sa

دول مجلس التعاون الخليجي الأخرى:
يرجى التواصل مع الهيئة المعنية ذات الصلة

مجلس وزارات الصحة العربية
هذا المنتج دوائي
قد تؤثر المنتجات الدوائية على صحتك، ويعد استهلاكه بخلاف الطريقة المحددة أمرًا خطيرًا.
اتبع وصفة الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء بدقة.
الطبيب والصيدلي خبراء في المنتجات الدوائية وفوائدها ومخاطرها.
لا تقطع فترة العلاج المحددة لك من تلقاء نفسك.
لا تكرر استخدام نفس الوصفة الطبية دون استشارة طبيبك.
احتفظ بجميع المنتجات الدوائية بعيدًا عن متناول الأطفال.






مجلس وزارات الصحة العربية
اتحاد الصيادلة العرب


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valcyte 450 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 496.3 mg of valganciclovir hydrochloride equivalent to 450 mg of valganciclovir (as free base).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets

Pink, convex oval film-coated tablets, with “VGC” embossed on one side and “450” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Valcyte is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte is indicated for the prevention of CMV disease in CMV-negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMV-positive donor.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Posology</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Caution &ndash; Strict adherence to dosage recommendations is essential to avoid overdose (see sections 4.4 and 4.9).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valganciclovir is rapidly and extensively metabolised to ganciclovir after oral dosing. Oral valganciclovir 900&nbsp;mg b.i.d. is therapeutically equivalent to intravenous ganciclovir 5&nbsp;mg/kg b.i.d.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Treatment of cytomegalovirus (CMV) retinitis&nbsp;</strong></p><p dir="ltr"><strong>Adult patients</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Induction treatment of CMV retinitis</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For patients with active CMV retinitis, the recommended dose is 900&nbsp;mg valganciclovir (two Valcyte 450&nbsp;mg tablets) twice a day for 21&nbsp;days and, whenever possible, taken with food.&nbsp; Prolonged induction treatment may increase the risk of bone marrow toxicity (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Maintenance treatment of CMV retinitis:</strong></p><p dir="ltr"><strong>Following induction treatment, or in patients with inactive CMV retinitis, the recommended dose is 900mg valganciclovir (two Valcyte 450&nbsp;mg tablets) once daily and, whenever possible, taken with food. Patients whose retinitis worsens may repeat induction treatment; however, consideration should be given to the possibility of viral drug resistance.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The duration of maintenance treatment should be determined on an individual basis.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The safety and efficacy of Valcyte in the treatment of CMV retinitis have not been established in adequate and well-controlled clinical studies in paediatric patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prevention of CMV disease in solid organ transplantation</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adult patients</strong></p><p dir="ltr"><strong>For kidney transplant patients, the recommended dose is 900 mg (two Valcyte 450&nbsp;mg tablets) once daily, starting within 10 days&nbsp; post-transplantation and continuing until 100 days post-transplantation. Prophylaxis may be continued until 200 days post-transplantation (see sections 4.4, 4.8 and 5.1).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For patients who have received a solid organ transplant other than kidney, the recommended dose is 900&nbsp;mg (two Valcyte 450&nbsp;mg tablets) once daily, starting within 10 days post-transplantation and continuing until 100&nbsp;days posttransplantation.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Whenever possible, the tablets should be taken with food.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p dir="ltr"><strong>In paediatric solid organ transplant patients, aged from birth, who are at risk of developing CMV disease, the recommended once daily dose of Valcyte is based on body surface area (BSA) and creatinine clearance (Clcr) derived from Schwartz formula (ClcrS), and is calculated using the equation below:</strong></p><p dir="ltr"><strong>Paediatric Dose (mg) = 7 x BSA x ClcrS (see Mosteller BSA formula and Schwartz Creatinine Clearance formula below).&nbsp;&nbsp;</strong></p><p dir="ltr"><strong>If the calculated Schwartz creatinine clearance exceeds 150 mL/min/1.73m2, then a maximum value of 150 mL/min/1.73m2 should be used in the equation:</strong></p><p dir="ltr"><strong><img width="332" height="47" src="https://lh6.googleusercontent.com/wUPwsxx4RAa9xOQgf2mALr5slF9rTDpyXil3wX0sXKvXb1R9kODqgmo9DroRapnrEieeEcx-cDYWv-pLep8SfGyhapQkjARvUCl9cVQSZO5MbI8Jo89BuTHA17isjpaoedTXdqw" /></strong></p><p>&nbsp;</p><p dir="ltr"><strong><img width="546" height="46" src="https://lh5.googleusercontent.com/B5Pkg2BkBDGTpAqJaGJ60ocHmw5UXE6WMqsIhoPjfQ_UN14140SUsY0y8B8km1seWNT5MO5xMw5gDJm16z48K4yWDGegJYSOMYsXmcTEDF-JAZoJ4zE_Ao88HDyQAx4w0hlZIuw" /></strong></p><p dir="ltr"><strong>where k = 0.45* for patients aged &lt; 2 years, 0.55 for boys aged 2 to &lt; 13 years and girls aged 2 to 16 years, and 0.7 for boys aged 13 to 16 years. Refer to adult dosing for patients older than 16 years of age.</strong></p><p dir="ltr"><strong>The k values provided are based on the Jaffe method of measuring serum creatinine and may require correction when enzymatic methods are used.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>*For appropriate sub-populations a lowering of k&nbsp;value may also be necessary (e.g. in paediatric patients with low birth weight).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For paediatric kidney transplant patients, the recommended once daily mg dose (7&nbsp;x&nbsp;BSA&nbsp;x&nbsp;ClcrS) should start within 10 days post-transplantation and continue until 200 days post-transplantation.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For paediatric patients who have received a solid organ transplant other than kidney, the recommended once daily mg dose (7x BSA x ClcrS) should start within 10 days post-transplantation and continue until 100 days posttransplantation.</strong></p><p dir="ltr"><strong>All calculated doses should be rounded to the nearest 25 mg increment for the actual deliverable dose. If the calculated dose exceeds 900 mg, a maximum dose of 900 mg should be administered.&nbsp; The oral solution is the preferred formulation since it provides the ability to administer a dose calculated according to the formula above; however, Valcyte film-coated tablets may be used if the calculated doses are within 10% of available tablet doses, and the patient is able to swallow tablets.&nbsp; For example, if the calculated dose is between 405 mg and 495 mg, one 450 mg tablet may be taken.&nbsp;</strong></p><p dir="ltr"><strong>It is recommended to monitor serum creatinine levels regularly and consider changes in height and body weight and adapt the dose as appropriate during the prophylaxis period.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Special dosage instructions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population:</strong></p><p dir="ltr"><strong>Dosing of paediatric SOT patients is individualised based on a patient&rsquo;s renal function, together with body surface area.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elderly patients:</strong></p><p dir="ltr"><strong>Safety and efficacy have not been established in this patient population. No studies have been conducted in adults older than 65 years of age. Since renal clearance decreases with age, Valcyte should be administered to elderly patients with special consideration of their renal status (see table below) (See section 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with renal impairment:</strong></p><p dir="ltr"><strong>Serum creatinine levels or estimated creatinine clearance should be monitored carefully. Dosage adjustment is required according to creatinine clearance, as shown in the table below (see sections 4.4 and 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>An estimated creatinine clearance (ml/min) can be related to serum creatinine by the following formulae:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For males = (140 &ndash; age [years]) &times; (body weight [kg]) &nbsp;</strong></p><p dir="ltr"><strong>(72) &times; (0.011 &times; serum creatinine [micromol/l])</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For females = 0.85 &times; male value</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Clcr (ml/min)</strong></p></td><td><p dir="ltr"><strong>Induction dose of valganciclovir</strong></p></td><td><p dir="ltr"><strong>Maintenance/Prevention dose of valganciclovir</strong></p></td></tr><tr><td><p dir="ltr"><strong>&ge; 60</strong></p></td><td><p dir="ltr"><strong>900&nbsp;mg (2 tablets) twice daily</strong></p></td><td><p dir="ltr"><strong>900&nbsp;mg (2 tablets) once daily</strong></p></td></tr><tr><td><p dir="ltr"><strong>40 &ndash; 59</strong></p></td><td><p dir="ltr"><strong>450&nbsp;mg (1 tablet) twice daily</strong></p></td><td><p dir="ltr"><strong>450&nbsp;mg (1 tablet) once daily</strong></p></td></tr><tr><td><p dir="ltr"><strong>25 &ndash; 39</strong></p></td><td><p dir="ltr"><strong>450&nbsp;mg (1 tablet) once daily</strong></p></td><td><p dir="ltr"><strong>450&nbsp;mg (1 tablet) every 2 days</strong></p></td></tr><tr><td><p dir="ltr"><strong>10 &ndash; 24</strong></p></td><td><p dir="ltr"><strong>450&nbsp;mg (1 tablet) every 2 days</strong></p></td><td><p dir="ltr"><strong>450&nbsp;mg (1 tablet) twice weekly</strong></p></td></tr><tr><td><p dir="ltr"><strong>&lt; 10</strong></p></td><td><p dir="ltr"><strong>Not recommended</strong></p></td><td><p dir="ltr"><strong>Not recommended</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Patients undergoing haemodialysis:</strong></p><p dir="ltr"><strong>For patients on haemodialysis (Clcr &lt; 10&nbsp;ml/min) a dose recommendation cannot be given.&nbsp; Thus Valcyte film-coated tablets should not be used in these patients (see sections 4.4 and 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with hepatic impairment:</strong></p><p dir="ltr"><strong>Safety and efficacy of Valcyte tablets have not been established in patients with hepatic impairment (see section 5.2).</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with severe leukopenia, neutropenia, anaemia, thrombocytopenia and pancytopenia:&nbsp;</strong></p><p dir="ltr"><strong>See section 4.4 before initiation of therapy.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>If there is a significant deterioration of blood cell counts during therapy with Valcyte, treatment with haematopoietic growth factors and/or dose interruption should be considered (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Method of administration</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte is administered orally, and whenever possible, should be taken with food (see section 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>For paediatric patients who are unable to swallow Valcyte film-coated tablets, Valcyte powder for oral solution can be administered.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Precautions to be taken before handling or administering the medicinal product&nbsp;</strong></p><p dir="ltr"><strong>The tablets should not be broken or crushed. Since Valcyte is considered a potential teratogen and carcinogen in humans, caution should be observed in handling broken tablets (see section 4.4). Avoid direct contact of broken or crushed tablets with skin or mucous membranes.&nbsp; If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valcyte is contra-indicated in patients with hypersensitivity to valganciclovir, ganciclovir or to any of the excipients listed in section 6.1.

Valcyte is contra-indicated during breast-feeding (see section 4.6).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Cross-hypersensitivity</strong></p><p dir="ltr"><strong>Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible. Caution should therefore be used when prescribing Valcyte to patients with known hypersensitivity to aciclovir or penciclovir, (or to their prodrugs, valaciclovir or famciclovir respectively).&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mutagenicity, teratogenicity, carcinogenicity, fertility, and contraception</strong></p><p dir="ltr"><strong>Prior to the initiation of valganciclovir treatment, patients should be advised of the potential risks to the fetus.&nbsp; In animal studies, ganciclovir was found to be mutagenic, teratogenic, carcinogenic, and a suppressor of fertility. Valcyte should, therefore, be considered a potential teratogen and carcinogen in humans with the potential to cause birth defects and cancers (see section 5.3). Based on clinical and nonclinical studies it is also considered likely that Valcyte causes temporary or permanent inhibition of spermatogenesis. Women of child bearing potential must be advised to use effective contraception during and for at least 30 days after treatment. Men must be advised to practise barrier contraception during treatment, and for at least 90 days thereafter, unless it is certain that the female partner is not at risk of pregnancy (see sections 4.6, 4.8 and 5.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valganciclovir has the potential to cause carcinogenicity and reproductive toxicity in the long term.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Myelosuppression</strong></p><p dir="ltr"><strong>Severe leukopenia, neutropenia, anaemia, thrombocytopenia, pancytopenia, bone marrow failure and aplastic anaemia have been observed in patients treated with Valcyte (and ganciclovir). Therapy should not be initiated if the absolute neutrophil count is less than 500&nbsp;cells/&mu;l, or the platelet count is less than 25000/&mu;l, or the haemoglobin level is less than 8&nbsp;g/dl (see sections 4.2 and 4.8).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>When extending prophylaxis beyond 100 days the possible risk of developing leukopenia and neutropenia should be taken into account (see sections 4.2, 4.8 and 5.1).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte should be used with caution in patients with pre-existing haematological cytopenia or a history of drug-related haematological cytopenia and in patients receiving radiotherapy.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>It is recommended that complete blood counts and platelet counts should be monitored regularly during therapy.&nbsp; Increased haematological monitoring may be warranted in patients with renal impairment and paediatrics, at a minimum each time the patient attends the transplant clinic.&nbsp; In patients developing severe leukopenia, neutropenia, anaemia and/or thrombocytopenia, it is recommended that treatment with haematoplioietic growth factors and/or dose interruption be considered (see section 4.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Difference in bioavailability with oral ganciclovir&nbsp;</strong></p><p dir="ltr"><strong>The bioavailability of ganciclovir after a single dose of 900&nbsp;mg valganciclovir is approximately 60&nbsp;%, compared with approximately 6&nbsp;% after administration of 1000&nbsp;mg oral ganciclovir (as capsules). Excessive exposure to ganciclovir may be associated with life-threatening adverse reactions.&nbsp; Therefore, careful adherence to the dose recommendations is advised when instituting therapy, when switching from induction to maintenance therapy and in patients who may switch from oral ganciclovir to valganciclovir as Valcyte cannot be substituted for ganciclovir capsules on a one-to-one basis.&nbsp; Patients switching from ganciclovir capsules should be advised of the risk of overdosage if they take more than the prescribed number of Valcyte tablets (see sections 4.2 and 4.9).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Renal impairment</strong></p><p dir="ltr"><strong>In patients with impaired renal function, dosage adjustments based on creatinine clearance are required (see sections 4.2 and 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte film-coated tablets should not be used in patients on haemodialysis (see sections 4.2 and 5.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Use with other medicines</strong></p><p dir="ltr"><strong>Seizures have been reported in patients taking imipenem-cilastatin and ganciclovir. Valcyte should not be used concomitantly with imipenem-cilastatin unless the potential benefits outweigh the potential risks (see section 4.5).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients treated with Valcyte and (a) didanosine, (b) drugs that are known to be myelosuppressive (e.g. zidovudine), or (c) substances affecting renal function, should be closely monitored for signs of added toxicity (see section 4.5).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The controlled clinical study using valganciclovir for the prophylactic treatment of CMV disease in transplantation, as detailed in section 5.1, did not include lung and intestinal transplant patients.&nbsp; Therefore, experience in these transplant patients is limited.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Drug interactions with valganciclovir</strong></p><p dir="ltr"><strong>In-vivo drug interaction studies with Valcyte have not been performed.&nbsp; Since valganciclovir is extensively and rapidly metabolised to ganciclovir; drug interactions associated with ganciclovir will be expected for valganciclovir.</strong></p><p><br /><br /><br /><br /><br /><br /><br /><br /><br />&nbsp;</p><p dir="ltr"><strong>Drug interactions with ganciclovir</strong></p><p dir="ltr"><strong>Pharmacokinetic interactions</strong></p><p dir="ltr"><strong>Probenecid&nbsp;</strong></p><p dir="ltr"><strong>Probenecid given with oral ganciclovir resulted in statistically significantly decreased renal clearance of ganciclovir (20&nbsp;%) leading to statistically significantly increased exposure (40&nbsp;%).&nbsp; These changes were consistent with a mechanism of interaction involving competition for renal tubular secretion.&nbsp; Therefore, patients taking probenecid and valganciclovir should be closely monitored for ganciclovir toxicity.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Didanosine</strong></p><p dir="ltr"><strong>Didanosine plasma concentrations were found to be consistently raised when given with IV ganciclovir. At intravenous doses of 5 and 10&nbsp;mg/kg/day, an increase in the AUC of didanosine ranging from 38 to 67% has been observed confirming a pharmacokinetic interaction during the concomitant administration of these drugs. There was no significant effect on ganciclovir concentrations. Patients should be closely monitored for didanosine toxicity e.g pancreatitis (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Other antiretrovirals</strong></p><p dir="ltr"><strong>Cytochrome P450 isoenzymes play no role in ganciclovir pharmacokinetics.&nbsp; As a consequence, pharmacokinetic interactions with protease inhibitors and nonnucleoside reverse transcriptase inhibitors are not anticipated.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacodynamic interactions</strong></p><p dir="ltr"><strong>Imipenem-cilastatin</strong></p><p dir="ltr"><strong>Seizures have been reported in patients taking ganciclovir and imipenem-cilastatin concomitantly and a pharmacodynamic interaction between these two drugs cannot be discounted. These drugs should not be used concomitantly unless the potential benefits outweigh the potential risks (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Zidovudine</strong></p><p dir="ltr"><strong>Both zidovudine and ganciclovir have the potential to cause neutropenia and anaemia. A pharmacodynamic interaction may occur during concomitant administration of these drugs. Some patients may not tolerate concomitant therapy at full dosage (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Potential drug interactions</strong></p><p dir="ltr"><strong>Toxicity may be enhanced when ganciclovir/valganciclovir is co-administered with other drugs known to be myelosuppressive or associated with renal impairment. This includes nucleoside (e.g. zidovudine, didanosine, stavudine) and nucleotide analogues (e.g. tenofovir, adefovir), immunosuppressants (e.g. ciclosporin, tacrolimus, mycophenolate mofetil), antineoplastic agents (e.g. doxorubicin, vinblastine, vincristine, hydroxyurea) and anti-infective agents (trimethoprim/sulphonamides, dapsone, amphotericin B, flucytosine, pentamidine). Therefore, these drugs should only be considered for concomitant use with valganciclovir if the potential benefits outweigh the potential risks (see section 4.4).</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Contraception in males and females</strong></p><p dir="ltr"><strong>As a result of the potential for reproductive toxicity and teratogenicity, women of childbearing potential must be advised to use effective contraception during and for at least 30 days after treatment. Male patients must be advised to practice barrier contraception during and for at least 90 days following treatment with valganciclovir unless it is certain that the female partner is not at risk of pregnancy (see sections 4.4 and 5.3).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pregnancy</strong></p><p dir="ltr"><strong>The safety of Valcyte for use in pregnant women has not been established.&nbsp; Its active metabolite, ganciclovir, readily diffuses across the human placenta.&nbsp; Based on its pharmacological mechanism of action and reproductive toxicity observed in animal studies with ganciclovir (see section 5.3) there is a theoretical risk of teratogenicity in humans.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte should not be used in pregnancy unless the therapeutic benefit for the mother outweighs the potential risk of teratogenic damage to the fetus.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Breast-feeding</strong></p><p dir="ltr"><strong>It is unknown if ganciclovir is excreted in human breast milk, but the possibility of ganciclovir being excreted in the breast milk and causing serious adverse reactions in the nursing infant cannot be discounted. Animal data indicate that ganciclovir is excreted in the milk of lactating rats. Therefore, breast-feeding must be discontinued during treatment with valganciclovir (see sections 4.3 and 5.3).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Fertility</strong></p><p dir="ltr"><strong>A small clinical study with renal transplant patients receiving Valcyte for CMV prophylaxis for up to 200 days demonstrated an impact of valganciclovir on spermatogenesis, with decreased sperm density and motility measured after treatment completion. This effect appears to be reversible and approximately six months after Valcyte discontinuation, mean sperm density and motility recovered to levels comparable to those observed in the untreated controls.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In animal studies, ganciclovir impaired fertility in male and female mice and has shown to inhibit spermatogenesis and induce testicular atrophy in mice, rats and dogs at doses considered clinically relevant.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Based on clinical and nonclinical studies, it is considered likely that ganciclovir (and valganciclovir) may cause temporary or permanent inhibition of human spermatogenesis (see sections 4.4 and 5.3).</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>No studies on the effects on ability to drive and use machines have been performed.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adverse reactions such as seizures, dizziness, and confusion have been reported with the use of Valcyte and/or ganciclovir. If they occur, such effects may affect tasks requiring alertness, including the patient&rsquo;s ability to drive and operate machinery.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Summary of the safety profile</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valganciclovir is a prodrug of ganciclovir, which is rapidly and extensively metabolised to ganciclovir after oral administration. The undesirable effects known to be associated with ganciclovir use can be expected to occur with valganciclovir. All of the adverse drug reactions observed in valganciclovir clinical studies have been previously observed with ganciclovir. Therefore, adverse drug reactions reported with IV or oral ganciclovir (formulation no longer available) or with valganciclovir are included in the table of adverse drug reactions below.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In patients treated with valganciclovir/ganciclovir the most serious and frequent adverse drug reactions are haematological reactions and include neutropenia, anaemia and thrombocytopenia &ndash; see section 4.4.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The frequencies presented in the table of adverse reactions are derived from a pooled population of patients (n=1704) receiving maintenance therapy with ganciclovir or valganciclovir. Exception is made for anaphylactic reaction, agranulocytosis and granulocytopenia, the frequencies of which are derived from post-marketing experience. Adverse reactions are listed according to MedDRA system organ class. Frequency categories are defined using the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) and very rare (&lt; 1/10,000).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The overall safety profile of ganciclovir/valganciclovir is consistent in HIV and transplant populations except that retinal detachment has only been reported in patients with CMV retinitis. However, there are some differences in the frequency of certain reactions. Valganciclovir is associated with a higher risk of diarrhoea compared to intravenous ganciclovir. Pyrexia, candida infections, depression, severe neutropenia (ANC &lt;500/&mu;L) and skin reactions are reported more frequently in patients with HIV. Renal and hepatic dysfunction are reported more frequently in organ transplant recipients.</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>b Tabulated list of adverse drug reactions</strong></p><p><br />&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>ADR</strong></p><p dir="ltr"><strong>(MedDRA)&nbsp;</strong></p><p dir="ltr"><strong>System Organ Class</strong></p></td><td><p dir="ltr"><strong>Frequency Category</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Infections and infestations:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Candida infections including oral candidiasis.</strong></p></td><td rowspan="2"><p dir="ltr"><strong>Very common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Upper respiratory tract infection</strong></p></td></tr><tr><td><p dir="ltr"><strong>Sepsis&nbsp;</strong></p></td><td rowspan="4"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Influenza</strong></p></td></tr><tr><td><p dir="ltr"><strong>Urinary tract infection</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cellulitis</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Blood and lymphatic disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Neutropenia</strong></p></td><td rowspan="2"><p dir="ltr"><strong>Very common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anaemia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Thrombocytopenia</strong></p></td><td rowspan="3"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Leukopenia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pancytopenia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Bone marrow failure</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Aplastic anaemia</strong></p></td><td rowspan="3"><p dir="ltr"><strong>Rare</strong></p></td></tr><tr><td><p dir="ltr"><strong>Agranulocytosis*</strong></p></td></tr><tr><td><p dir="ltr"><strong>Granulocytopenia*</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Immune system disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypersensitivity</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anaphylactic reaction*</strong></p></td><td><p dir="ltr"><strong>Rare</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Metabolic and nutrition disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Decreased appetite&nbsp;</strong></p></td><td><p dir="ltr"><strong>Very common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Weight decreased</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Psychiatric disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Depression</strong></p></td><td rowspan="3"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Confusional state</strong></p></td></tr><tr><td><p dir="ltr"><strong>Anxiety</strong></p></td></tr><tr><td><p dir="ltr"><strong>Agitation</strong></p></td><td rowspan="4"><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Psychotic disorder</strong></p></td></tr><tr><td><p dir="ltr"><strong>Thinking abnormal</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hallucinations</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Nervous system disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Headache</strong></p></td><td><p dir="ltr"><strong>Very common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Insomnia</strong></p></td><td rowspan="7"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Neuropathy peripheral</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dizziness</strong></p></td></tr><tr><td><p dir="ltr"><strong>Paraesthesia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hypoaesthesia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Seizure</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dysgeusia (taste disturbance)</strong></p></td></tr><tr><td><p dir="ltr"><strong>Tremor</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Eye disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Visual impairment</strong></p></td><td rowspan="6"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Retinal detachment**</strong></p></td></tr><tr><td><p dir="ltr"><strong>Vitreous floaters</strong></p></td></tr><tr><td><p dir="ltr"><strong>Eye pain</strong></p></td></tr><tr><td><p dir="ltr"><strong>Conjunctivitis</strong></p></td></tr><tr><td><p dir="ltr"><strong>Macular oedema</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Ear and labyrinth disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Ear pain</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Deafness</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Cardiac disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Arrhythmias</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Vascular disorders:</strong></p></td><td>&nbsp;</td></tr><tr><td><p dir="ltr"><strong>Hypotension</strong></p></td><td><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Respiratory, thoracic and mediastinal disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cough</strong></p></td><td rowspan="2"><p dir="ltr"><strong>Very common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dyspnoea</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Gastrointestinal disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Diarrhoea</strong></p></td><td rowspan="4"><p dir="ltr"><strong>Very common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Nausea</strong></p></td></tr><tr><td><p dir="ltr"><strong>Vomiting</strong></p></td></tr><tr><td><p dir="ltr"><strong>Abdominal pain</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dyspepsia</strong></p></td><td rowspan="8"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Flatulence</strong></p></td></tr><tr><td><p dir="ltr"><strong>Abdominal pain upper</strong></p></td></tr><tr><td><p dir="ltr"><strong>Constipation</strong></p></td></tr><tr><td><p dir="ltr"><strong>Mouth ulceration</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dysphagia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Abdominal distention</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pancreatitis</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Hepato-biliary disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Blood alkaline phosphatase increased</strong></p></td><td rowspan="4"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Hepatic function abnormal</strong></p></td></tr><tr><td><p dir="ltr"><strong>Aspartate aminotransferase increased</strong></p></td></tr><tr><td><p dir="ltr"><strong>Alanine aminotransferase increased</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Skin and subcutaneous tissues disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dermatitis</strong></p></td><td><p dir="ltr"><strong>Very common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Night sweats</strong></p></td><td rowspan="4"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pruritus</strong></p></td></tr><tr><td><p dir="ltr"><strong>Rash</strong></p></td></tr><tr><td><p dir="ltr"><strong>Alopecia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Dry skin</strong></p></td><td rowspan="2"><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Urticaria</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Musculo-skeletal and connective tissue disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Back pain</strong></p></td><td rowspan="4"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Myalgia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Arthralgia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Muscle spasms</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Renal and urinary disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Renal impairment</strong></p></td><td rowspan="3"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Creatinine clearance renal decreased&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Blood creatinine increased&nbsp;&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>Renal failure</strong></p></td><td rowspan="2"><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td><p dir="ltr"><strong>Haematuria</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>Reproductive system and breast disorders:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Infertility male</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr><tr><td colspan="2"><p dir="ltr"><strong>General disorders and administration site conditions:</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pyrexia</strong></p></td><td rowspan="2"><p dir="ltr"><strong>Very common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Fatigue</strong></p></td></tr><tr><td><p dir="ltr"><strong>Pain</strong></p></td><td rowspan="4"><p dir="ltr"><strong>Common</strong></p></td></tr><tr><td><p dir="ltr"><strong>Chills</strong></p></td></tr><tr><td><p dir="ltr"><strong>Malaise</strong></p></td></tr><tr><td><p dir="ltr"><strong>Asthenia</strong></p></td></tr><tr><td><p dir="ltr"><strong>Chest pain</strong></p></td><td><p dir="ltr"><strong>Uncommon</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>*The frequencies of these adverse reactions are derived from post-marketing experience</strong></p><p dir="ltr"><strong>**Retinal detachment has only been reported in HIV patients treated for CMV retinitis</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>Description of selected adverse reactions</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Neutropenia</strong></p><p dir="ltr"><strong>The risk of neutropenia is not predictable on the basis of the number of neutrophils before treatment. Neutropenia usually occurs during the first or second week of induction therapy. The cell count usually normalises within 2 to 5 days after discontinuation of the drug or dose reduction (see section 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Thrombocytopenia</strong></p><p dir="ltr"><strong>Patients with low baseline platelet counts (&lt; 100,000 /&mu;L) have an increased risk of developing thrombocytopenia. Patients with iatrogenic immunosuppression due to treatment with immunosuppressive drugs are at greater risk of thrombocytopenia than patients with AIDS (see section 4.4). Severe thrombocytopenia may be associated with potentially life-threatening bleeding.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Influence of treatment duration or indication on adverse reactions</strong></p><p dir="ltr"><strong>Severe neutropenia (ANC &lt;500/&mu;L) is seen more frequently in CMV retinitis patients (14%) undergoing treatment with valganciclovir, intravenous or oral ganciclovir than in solid organ transplant patients receiving valganciclovir or oral ganciclovir. In patients receiving valganciclovir or oral ganciclovir until Day 100 post-transplant, the incidence of severe neutropenia was 5% and 3% respectively, whilst in patients receiving valganciclovir until Day 200 post-transplant the incidence of severe neutropenia was 10%.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>There was a greater increase in serum creatinine seen in solid organ transplant patients treated until Day 100 or Day 200 post-transplant with both valganciclovir and oral ganciclovir when compared to CMV retinitis patients. However, impaired renal function is a feature common in solid organ transplantation patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The overall safety profile of Valcyte did not change with the extension of prophylaxis up to 200 days in high risk kidney transplant patients. Leukopenia was reported with a slightly higher incidence in the 200 days arm while the incidence of neutropenia, anaemia and thrombocytopenia were similar in both arms.</strong></p><p><br />&nbsp;</p><p dir="ltr"><strong>c Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valcyte has been studied in 179 paediatric solid organ transplant patients who were at risk of developing CMV disease (aged 3 weeks to 16 years) and in 133&nbsp;neonates with symptomatic congenital CMV disease (aged 2 to 31 days), with duration of ganciclovir exposure ranging from 2 to 200 days.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The most frequently reported adverse reactions on treatment in paediatric clinical trials were diarrhoea, nausea, neutropenia, leukopenia and anaemia.&nbsp;</strong></p><p dir="ltr"><strong>In solid organ transplant patients, the overall safety profile was similar in paediatric patients as compared to adults.&nbsp; Neutropenia was reported with slightly higher incidence in the two studies conducted in paediatric solid organ transplant patients as compared to adults, but there was no correlation between neutropenia and infectious adverse events in the paediatric population. A higher risk of cytopenias in neonates and infants warrants careful monitoring of blood counts in these age groups (see section 4.4).&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In kidney transplant paediatric patients, prolongation of valganciclovir exposure up to 200 days was not associated with an overall increase in the incidence of adverse events.&nbsp; The incidence of severe neutropenia (ANC&nbsp;&lt;&nbsp;500/&micro;L) was higher in paediatric kidney patients treated until Day 200 as compared to paediatric patients treated until Day 100 and as compared to adult kidney transplant patients treated until Day 100 or Day 200 (see section 4.4).</strong></p><p dir="ltr"><strong>Only limited data are available in neonates or infants with symptomatic congenital CMV infection treated with Valcyte, however the safety appears to be consistent with the known safety profile of valganciclovir/ganciclovir.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reporting of suspected adverse reactions</strong></p><p dir="ltr"><strong>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</strong></p><p dir="ltr"><strong>To reports any side effect(s):</strong></p><p dir="ltr"><strong>&bull;&nbsp; &nbsp; Saudi Arabia:</strong></p><table><tbody><tr><td><ul><li dir="ltr"><p dir="ltr"><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p></li></ul><ul><li dir="ltr"><p dir="ltr"><strong>Fax: +966-11-205-7662</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</strong></p></li><li dir="ltr"><p dir="ltr"><strong>SFDA call center: 19999</strong></p></li><li dir="ltr"><p dir="ltr"><strong>E-mail: npc.drug@sfda.gov.sa</strong></p></li><li dir="ltr"><p dir="ltr"><strong>Website: www.sfda.gov.sa/npc</strong></p></li></ul></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>&bull;&nbsp; &nbsp; Other GCC States:</strong></p><table><tbody><tr><td><ul><li dir="ltr"><p dir="ltr"><strong>Please contact the relevant competent authority.</strong></p></li></ul></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Overdose experience with valganciclovir and intravenous ganciclovir</strong></p><p dir="ltr"><strong>It is expected that an overdose of valganciclovir could possibly result in increased renal toxicity (see sections 4.2 and 4.4).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Reports of overdoses with intravenous ganciclovir, some with fatal outcomes, have been received from clinical trials and during post-marketing experience. In some of these cases no adverse events were reported. The majority of patients experienced one or more of the following adverse events:</strong></p><p>&nbsp;</p><p dir="ltr"><strong>- Haematological toxicity: myelosuppression including pancytopenia, bone marrow failure, leukopenia, neutropenia, granulocytopenia.</strong></p><p dir="ltr"><strong>- Hepatotoxicity: hepatitis, liver function disorder.</strong></p><p dir="ltr"><strong>- Renal toxicity: worsening of haematuria in a patient with pre-existing renal impairment, acute kidney injury, elevated creatinine.</strong></p><p dir="ltr"><strong>- Gastrointestinal toxicity: abdominal pain, diarrhoea, vomiting.</strong></p><p dir="ltr"><strong>- Neurotoxicity: generalised tremor, seizure.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Haemodialysis and hydration may be of benefit in reducing blood plasma levels in patients who receive an overdose of valganciclovir (see section 5.2).</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Pharmacotherapeutic group: antivirals for systemic use, nucleosides and nucleotides excl. reverse transcriptase inhibitors, ATC code: J05A B14.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Mechanism of action</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valganciclovir is an L-valyl ester (prodrug) of ganciclovir. After oral administration, valganciclovir is rapidly and extensively metabolised to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2&rsquo;-deoxyguanosine and inhibits replication of herpes viruses in vitro and in vivo. Sensitive human viruses include human cytomegalovirus (HCMV), herpes simplex virus-1 and -2 (HSV-1 and HSV-2), human herpes virus -6, -7 and -8 (HHV-6, HHV-7, HHV8), Epstein-Barr virus (EBV), varicella-zoster virus (VZV) and hepatitis B virus (HBV).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In CMV-infected cells, ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, pUL97. Further phosphorylation occurs by cellular kinases to produce ganciclovir triphosphate, which is then slowly metabolised intracellularly. Triphosphate metabolism has been shown to occur in HSV- and HCMV- infected cells with half-lives of 18 and between 6 and 24 hours respectively, after the removal of extracellular ganciclovir. As the phosphorylation is largely dependent on the viral kinase, phosphorylation of ganciclovir occurs preferentially in virus-infected cells.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The virustatic activity of ganciclovir is due to inhibition of viral DNA synthesis by: (a) competitive inhibition of incorporation of deoxyguanosine-triphosphate into DNA by viral DNA polymerase, and (b) incorporation of ganciclovir triphosphate into viral DNA causing termination of, or very limited, further viral DNA elongation.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Antiviral activity</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The in-vitro anti-viral activity, measured as IC50 of ganciclovir against CMV, is in the range of 0.08&nbsp;&mu;M (0.02&nbsp;&mu;g/ml) to 14&nbsp;&mu;M (3.5&nbsp;&mu;g/ml).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The clinical antiviral effect of Valcyte has been demonstrated in the treatment of AIDS patients with newly diagnosed CMV retinitis. CMV shedding was decreased in urine from 46&nbsp;% (32/69) of patients at study entry to 7&nbsp;% (4/55) of patients following four weeks of Valcyte treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Clinical efficacy and safety</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Adult patients</strong></p><p dir="ltr"><strong>Treatment of CMV retinitis:</strong></p><p dir="ltr"><strong>Patients with newly diagnosed CMV retinitis were randomised in one study to induction therapy with either Valcyte 900 mg&nbsp;b.i.d or intravenous ganciclovir 5&nbsp;mg/kg&nbsp;b.i.d. The proportion of patients with photographic progression of CMV retinitis at week 4 was comparable in both treatment groups, 7/70 and 7/71 patients progressing in the intravenous ganciclovir and valganciclovir arms respectively.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Following induction treatment dosing, all patients in this study received maintenance treatment with Valcyte given at the dose of 900 mg once daily. The mean (median) time from randomisation to progression of CMV retinitis in the group receiving induction and maintenance treatment with Valcyte was 226 (160) days and in the group receiving induction treatment with intravenous ganciclovir and maintenance treatment with Valcyte was 219 (125) days.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prevention of CMV disease in transplantation:</strong></p><p dir="ltr"><strong>A double-blind, double-dummy, clinical active comparator study has been conducted in heart, liver and kidney transplant patients (lung and gastro-intestinal transplant patients were not included in the study) at high-risk of CMV disease (D+/R-) who received either Valcyte (900&nbsp;mg od) or oral ganciclovir (1000&nbsp;mg t.i.d.) starting within 10 days of transplantation until Day 100 post-transplant. The incidence of CMV disease (CMV syndrome + tissue invasive disease) during the first 6&nbsp;months post-transplant was 12.1&nbsp;% in the Valcyte arm (n=239) compared with 15.2&nbsp;% in the oral ganciclovir arm (n=125). The large majority of cases occurred following cessation of prophylaxis (post-Day 100) with cases in the valganciclovir arm occurring on average later than those in the oral ganciclovir arm. The incidence of acute rejection in the first 6 months was 29.7&nbsp;% in patients randomised to valganciclovir compared with 36.0&nbsp;% in the oral ganciclovir arm, with the incidence of graft loss being equivalent, occurring in 0.8&nbsp;% of patients, in each arm.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A double-blind, placebo controlled study has been conducted in 326 kidney transplant patients at high risk of CMV disease (D+/R-) to assess the efficacy and safety of extending Valcyte CMV prophylaxis from 100 to 200 days post-transplant. Patients were randomized (1:1) to receive Valcyte tablets (900&nbsp;mg od) within 10 days of transplantation either until Day 200 post-transplant or until Day 100 post-transplant followed by 100 days of placebo.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The proportion of patients who developed CMV disease during the first 12 months post-transplant is shown in the table below.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Percentage of Kidney Transplant Patients with CMV Disease1, 12 Month ITT Population A</strong></p><table><tbody><tr><td>&nbsp;</td><td><p dir="ltr"><strong>Valganciclovir&nbsp;</strong></p>&nbsp;<p dir="ltr"><strong>900 mg od</strong></p><p dir="ltr"><strong>100 Days&nbsp;</strong></p><p dir="ltr"><strong>(N = 163)</strong></p></td><td><p dir="ltr"><strong>Valganciclovir&nbsp;</strong></p>&nbsp;<p dir="ltr"><strong>900 mg od</strong></p><p dir="ltr"><strong>200 Days</strong></p><p dir="ltr"><strong>(N = 155)</strong></p></td><td><p dir="ltr"><strong>Between Treatment Group Difference</strong></p></td></tr><tr><td><p dir="ltr"><strong>Patients with confirmed or assumed CMV disease2</strong></p></td><td><p dir="ltr"><strong>71 (43.6%)</strong></p><p dir="ltr"><strong>[35.8% ; 51.5%]</strong></p></td><td><p dir="ltr"><strong>36 (23.2%)</strong></p><p dir="ltr"><strong>[16.8% ; 30.7%]</strong></p></td><td><p dir="ltr"><strong>20.3%</strong></p><p dir="ltr"><strong>[9.9% ; 30.8%]</strong></p></td></tr><tr><td><p dir="ltr"><strong>Patients with confirmed CMV disease</strong></p></td><td><p dir="ltr"><strong>60 (36.8%)</strong></p><p dir="ltr"><strong>[29.4% ; 44.7%]</strong></p></td><td><p dir="ltr"><strong>25 (16.1%)</strong></p><p dir="ltr"><strong>[10.7% ; 22.9%]</strong></p></td><td><p dir="ltr"><strong>20.7%</strong></p><p dir="ltr"><strong>[10.9% ; 30.4%]</strong></p></td></tr></tbody></table><p dir="ltr"><strong>1 CMV Disease is defined as either CMV syndrome or tissue invasive CMV.&nbsp; 2 Confirmed CMV is a clinically confirmed case of CMV disease.&nbsp; Patients were assumed to have CMV disease if there was no week 52 assessment&nbsp;and no confirmation of CMV disease before this time point.</strong></p><p dir="ltr"><strong>A The results found up to 24 months were in line with the up to 12 month results: Confirmed or assumed CMV disease was 48.5% in the 100 days treatment arm versus 34.2% in the 200 days treatment arm; difference between the treatment groups was 14.3% [3.2 %; 25.3%].</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Significantly less high risk kidney transplant patients developed CMV disease following CMV prophylaxis with Valcyte until Day 200 post-transplant compared to patients who received CMV prophylaxis with Valcyte until Day 100 post-transplant.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The graft survival rate as well as the incidence of biopsy proven acute rejection was similar in both treatment groups. The graft survival rate at 12 months post-transplant was 98.2 % (160/163) for the 100 day dosing regimen and 98.1 % (152/155) for the 200 day dosing regimen. Up to 24 month post-transplant, four additional cases of graft loss were reported, all in the 100 days dosing group. The incidence of biopsy proven acute rejection at 12 months post-transplant was 17.2% (28/163) for the 100 day dosing regimen and 11.0% (17/155) for the 200 day dosing regimen. Up to 24 month post-transplant, one additional case has been reported in the 200 days dosing group.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Viral resistance</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Virus resistant to ganciclovir can arise after chronic dosing with valganciclovir by selection of mutations in the viral kinase gene (UL97) responsible for ganciclovir monophosphorylation and/or the viral polymerase gene (UL54). In clinical isolates, seven canonical UL97 substitutions, M460V/I, H520Q, C592G, A594V, L595S, C603W are the most frequently reported ganciclovir resistance-associated substitutions. Viruses containing mutations in the UL97 gene are resistant to ganciclovir alone, whereas viruses with mutations in the UL54 gene are resistant to ganciclovir but may show cross-resistance to other antivirals that also target the viral polymerase.</strong><br />&nbsp;</p><p dir="ltr"><strong>Treatment of CMV retinitis:</strong></p><p dir="ltr"><strong>Genotypic analysis of CMV in polymorphonuclear leucocytes (PMNL) isolates from 148 patients with CMV retinitis enrolled in one clinical study has shown that 2.2&nbsp;%, 6.5&nbsp;%, 12.8&nbsp;%, and 15.3&nbsp;% contain UL97 mutations after 3, 6, 12 and 18 months, respectively, of valganciclovir treatment.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prevention of CMV disease in transplantation:</strong></p><p dir="ltr"><strong>Active comparator study</strong></p><p dir="ltr"><strong>Resistance was studied by genotypic analysis of CMV in PMNL samples collected i) on Day 100 (end of study drug prophylaxis) and ii) in cases of suspected CMV disease up to 6 months after transplantation. From the 245 patients randomised to receive valganciclovir, 198 Day 100 samples were available for testing and no ganciclovir resistance mutations were observed. This compares with 2 ganciclovir resistance mutations detected in the 103 samples tested (1.9&nbsp;%) for patients in the oral ganciclovir comparator arm.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Of the 245 patients randomised to receive valganciclovir, samples from 50 patients with suspected CMV disease were tested and no resistance mutations were observed. Of the 127 patients randomised on the ganciclovir comparator arm, samples from 29 patients with suspected CMV disease were tested, from which two resistance mutations were observed, giving an incidence of resistance of 6.9&nbsp;%.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Extending prophylaxis study from 100 to 200 days post-transplant</strong></p><p dir="ltr"><strong>Genotypic analysis was performed on the UL54 and UL97 genes derived from virus extracted from 72 patients who met the resistance analysis criteria: patients who experienced a positive viral load (&gt; 600 copies/ml) at the end of prophylaxis and/or patients who had confirmed CMV disease up to 12 months (52 weeks) post-transplant. Three patients in each treatment group had a known ganciclovir resistance mutation.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Treatment of CMV retinitis:</strong></p><p dir="ltr"><strong>The European Medicines Agency has waived the obligation to perform studies with Valcyte in all subsets of the paediatric population in the treatment of infection due to CMV in immuno-compromised patients (see section 4.2 for information on paediatric use).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Prevention of CMV disease in transplantation</strong></p><p dir="ltr"><strong>A phase II pharmacokinetic and safety study in paediatric solid organ transplant recipients (aged 4 months to 16 years, n = 63) receiving valganciclovir once daily for up to 100 days according to the paediatric dosing algorithm (see section 4.2) produced exposures similar to that in adults (see section 5.2). Follow up after treatment was 12 weeks. CMV D/R serology status at baseline was D+/R- in 40%, D+/R+ in 38%, D-/R+ in 19% and D-/R- in 3% of the cases. Presence of CMV virus was reported in 7 patients. The observed adverse drug reactions were of similar nature as those in adults (see section 4.8).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A phase IV tolerability study in paediatric kidney transplant recipients (aged 1 to 16 years, n=57) receiving valganciclovir once daily for up to 200 days according to the dosing algorithm (see section 4.2) resulted in a low incidence of CMV.&nbsp; Follow up after treatment was 24 weeks. CMV D/R serology status at baseline was D+/R+ in 45%, D+/R- in 39%, D-/R+ in 7%, D-/R- in 7% and ND/R+ in 2% of the cases. CMV viremia was reported in 3 patients and a case of CMV syndrome was suspected in one patient but not confirmed by CMV PCR by the central laboratory. The observed adverse drug reactions were of similar nature to those in adults (see section 4.8).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>These data support the extrapolation of efficacy data from adults to children and provide posology recommendations for paediatric patients.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A phase I pharmacokinetic and safety study in heart transplant patients (aged 3 weeks to 125 days, n=14) who received a single daily dose of valganciclovir according to the paediatric dosing algorithm (see section 4.2) on 2&nbsp;consecutive days produced exposures similar to those in adults (see section 5.2). Follow up after treatment was 7 days. The safety profile was consistent with other paediatric and adult studies, although patient numbers and valganciclovir exposure were limited in this study.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Congenital CMV</strong></p><p dir="ltr"><strong>The efficacy and safety of ganciclovir and/or valganciclovir was studied in neonates and infants with congenital symptomatic CMV infection in two studies.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the first study, the pharmacokinetics and safety of a single dose of valganciclovir (dose range 14-16-20 mg/kg/dose) was studied in 24 neonates (aged 8 to 34 days) with symptomatic congenital CMV disease (see section 5.2). The neonates received 6 weeks of antiviral treatment, whereas 19 of the 24 patients received up to 4 weeks of treatment with oral valganciclovir, in the remaining 2 weeks they received i.v. ganciclovir. The 5 remaining patients received i.v. ganciclovir for the most time of the study period. In the second study the efficacy and safety of six weeks versus six months of valganciclovir treatment was studied in 109 infants aged 2 to 30 days with symptomatic congenital CMV disease.&nbsp; All infants received oral valganciclovir at a dose of 16 mg/kg b.i.d. for 6 weeks. After 6 weeks of treatment the infants were randomized 1:1 to continue treatment with valganciclovir at the same dose or receive a matched placebo to complete 6 months of treatment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>This treatment indication is not currently recommended for valganciclovir. The design of the studies and results obtained are too limited to allow appropriate efficacy and safety conclusions on valganciclovir.&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>The pharmacokinetic properties of valganciclovir have been evaluated in HIV- and CMV-seropositive patients, patients with AIDS and CMV retinitis and in solid organ transplant patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Dose proportionality with respect to ganciclovir AUC following administration of valganciclovir in the dose range 450 to 2625 mg was demonstrated only under fed conditions.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Absorption</strong></p><p dir="ltr"><strong>Valganciclovir is a prodrug of ganciclovir.&nbsp; It is well absorbed from the gastrointestinal tract and rapidly and extensively metabolised in the intestinal wall and liver to ganciclovir. Systemic exposure to valganciclovir is transient and low.&nbsp; The bioavailability of ganciclovir from oral dosing of valganciclovir is approximately 60&nbsp;% across all the patient populations studied and the resultant exposure to ganciclovir is similar to that after its intravenous administration (please see below). For comparison, the bioavailability of ganciclovir after administration of 1000 mg oral ganciclovir (as capsules) is 6&nbsp;&nbsp;8&nbsp;%.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valganciclovir in HIV positive, CMV positive patients:</strong></p><p dir="ltr"><strong>Systemic exposure of HIV positive , CMV positive patients after twice daily administration of ganciclovir and valganciclovir for one week is:</strong></p><p>&nbsp;</p><table><tbody><tr><td rowspan="2"><p dir="ltr"><strong>Parameter</strong></p></td><td rowspan="2"><p dir="ltr"><strong>Ganciclovir<br />(5&nbsp;mg/kg, i.v.)</strong></p><p dir="ltr"><strong>n = 18</strong></p></td><td colspan="2"><p dir="ltr"><strong>Valganciclovir (900&nbsp;mg, p.o.)</strong></p><p dir="ltr"><strong>n = 25</strong></p></td></tr><tr><td><p dir="ltr"><strong>Ganciclovir</strong></p></td><td><p dir="ltr"><strong>Valganciclovir</strong></p></td></tr><tr><td><p dir="ltr"><strong>AUC(0 - 12 h) (&mu;g.h/ml)</strong></p></td><td><p dir="ltr"><strong>28.6 &plusmn;&nbsp;9.0</strong></p></td><td><p dir="ltr"><strong>32.8 &plusmn;&nbsp;10.1</strong></p></td><td><p dir="ltr"><strong>0.37 &plusmn;&nbsp;0.22</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmax (&mu;g/ml)</strong></p></td><td><p dir="ltr"><strong>10.4 &plusmn;&nbsp;4.9</strong></p></td><td><p dir="ltr"><strong>6.7 &plusmn;&nbsp;2.1</strong></p></td><td><p dir="ltr"><strong>0.18 &plusmn;&nbsp;0.06</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>The efficacy of ganciclovir in increasing the time-to-progression of CMV retinitis has been shown to correlate with systemic exposure (AUC).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Valganciclovir in solid organ transplant patients:</strong></p><p dir="ltr"><strong>Steady state systemic exposure of solid organ transplant patients to ganciclovir after daily oral administration of ganciclovir and valganciclovir is:</strong></p><p>&nbsp;</p><table><tbody><tr><td rowspan="2"><p dir="ltr"><strong>Parameter</strong></p></td><td rowspan="2"><p dir="ltr"><strong>Ganciclovir<br />(1000&nbsp;mg t.i.d.)<br />n = 82</strong></p></td><td><p dir="ltr"><strong>Valganciclovir (900 mg, od)<br />n = 161</strong></p></td></tr><tr><td><p dir="ltr"><strong>Ganciclovir</strong></p></td></tr><tr><td><p dir="ltr"><strong>AUC(0 - 24 h) (&mu;g.h/ml)</strong></p></td><td><p dir="ltr"><strong>28.0 &plusmn;&nbsp;10.9</strong></p></td><td><p dir="ltr"><strong>46.3 &plusmn;&nbsp;15.2</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmax (&mu;g/ml)</strong></p></td><td><p dir="ltr"><strong>1.4 &plusmn;&nbsp;0.5</strong></p></td><td><p dir="ltr"><strong>5.3 &plusmn;&nbsp;1.5</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>The systemic exposure of ganciclovir to heart, kidney and liver transplant recipients was similar after oral administration of valganciclovir according to the renal function dosing algorithm.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Food effect:</strong></p><p dir="ltr"><strong>When valganciclovir was given with food at the recommended dose of 900&nbsp;mg, higher values were seen in both mean ganciclovir AUC (approximately 30&nbsp;%) and mean ganciclovir Cmax values (approximately 14&nbsp;%) than in the fasting state.&nbsp; Also, the inter-individual variation in exposure of ganciclovir decreases when taking Valcyte with food.&nbsp; Valcyte has only been administered with food in clinical studies.&nbsp; Therefore, it is recommended that Valcyte be administered with food (see section 4.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Distribution:</strong></p><p dir="ltr"><strong>Because of rapid conversion of valganciclovir to ganciclovir, protein binding of valganciclovir was not determined. The steady state volume of distribution (Vd) of ganciclovir after intravenous administration was 0.680 &plusmn; 0.161 l/kg (n=114). For IV ganciclovir, the volume of distribution is correlated with body weight with values for the steady state volume of distribution ranging from 0.54&minus;0.87 L/kg. Ganciclovir penetrates the cerebrospinal fluid. Binding to plasma proteins was 1%-2% over ganciclovir concentrations of 0.5 and 51 &micro;g/mL.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Biotransformation</strong></p><p dir="ltr"><strong>Valganciclovir is rapidly and extensively metabolised to ganciclovir; no other metabolites have been detected. Ganciclovir itself is not metabolised to a significant extent.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Elimination</strong></p><p dir="ltr"><strong>Following dosing with oral valganciclovir, the drug is rapidly hydrolysed to ganciclovir. Ganciclovir is eliminated from the systemic circulation by glomerular filtration and active tubular secretion.&nbsp; In patients with normal renal function greater than 90% of IV administered ganciclovir was recovered un-metabolized in the urine within 24 hours. In patients with normal renal function the post-peak plasma concentrations of ganciclovir after administration of valganciclovir decline with a half-life ranging from 0.4 h to 2.0 h.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacokinetics in special clinical situations</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Paediatric population</strong></p><p dir="ltr"><strong>In a phase II pharmacokinetic and safety study in paediatric solid organ transplant recipients (aged 4 months to 16 years, n = 63) valganciclovir was given once daily for up to 100 days. Pharmacokinetic parameters were similar across organ type and age range and comparable with adults. Population pharmacokinetic modeling suggested that bioavailability was approximately 60%. Clearance was positively influenced by both body surface area and renal function.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In a phase I pharmacokinetic and safety study in paediatric heart transplant recipients (aged 3 weeks to 125 days, n = 14), valganciclovir was given once daily for two study days. &nbsp; Population pharmacokinetics estimated that mean bioavailability was 64%.&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>A comparison of the results from these two studies and the pharmacokinetic results from the adult population shows that ranges of AUC&nbsp;0-24h were very similar across all age groups, including adults.&nbsp; Mean values for AUC024h and Cmax were also similar across the paediatric age groups &lt; 12 years old, although there was a trend of decreasing mean values for AUC0-24h and Cmax across the entire pediatric age range, which appeared to correlate with increasing age.&nbsp; This trend was more apparent for mean values of clearance and half-life (t1/2); however this is to be expected as clearance is influenced by changes in weight, height and renal function associated with patient growth, as indicated by population pharmacokinetic modelling.&nbsp;&nbsp;&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The following table summarizes the model-estimated AUC0-24h ranges for ganciclovir from these two studies, as well as mean and standard deviation values for AUC0-24h, Cmax, CL and t &frac12; for the relevant paediatric age groups compared to adult data:</strong></p><p><br /><br /><br /><br />&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>PK Parameter</strong></p></td><td><p dir="ltr"><strong>Adults*</strong></p></td><td colspan="4"><p dir="ltr"><strong>Paediatrics</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>&ge; 18 years</strong></p><p dir="ltr"><strong>(n=160)</strong></p></td><td><p dir="ltr"><strong>&lt; 4 months&nbsp;</strong></p><p dir="ltr"><strong>(n = 14)</strong></p></td><td><p dir="ltr"><strong>4 months - &le; 2 years&nbsp;</strong></p><p dir="ltr"><strong>(n=17)</strong></p></td><td><p dir="ltr"><strong>&gt; 2 - &lt; 12 years</strong></p><p dir="ltr"><strong>(n=21)</strong></p></td><td><p dir="ltr"><strong>&ge; 12 years &ndash; 16 years</strong></p><p dir="ltr"><strong>(n=25)</strong></p></td></tr><tr><td><p dir="ltr"><strong>AUC0-24h (&mu;g.h/ml)</strong></p></td><td><p dir="ltr"><strong>46.3 &plusmn;&nbsp;15.2</strong></p></td><td><p dir="ltr"><strong>68.1 &plusmn; 19.8</strong></p></td><td><p dir="ltr"><strong>64.3 &plusmn; 29.2</strong></p></td><td><p dir="ltr"><strong>59.2 &plusmn; 15.1</strong></p></td><td><p dir="ltr"><strong>50.3 &plusmn; 15.0</strong></p></td></tr><tr><td><p dir="ltr"><strong>Range of AUC0-24h</strong></p></td><td><p dir="ltr"><strong>15.4 &ndash; 116.1&nbsp;</strong></p></td><td><p dir="ltr"><strong>34 - 124</strong></p></td><td><p dir="ltr"><strong>34 - 152</strong></p></td><td><p dir="ltr"><strong>36 - 108</strong></p></td><td><p dir="ltr"><strong>22 - 93</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmax (&mu;g/ml)</strong></p></td><td><p dir="ltr"><strong>5.3 &plusmn;&nbsp;1.5</strong></p></td><td><p dir="ltr"><strong>10.5 &plusmn; 3.36</strong></p></td><td><p dir="ltr"><strong>10.3 &plusmn; 3.3</strong></p></td><td><p dir="ltr"><strong>9.4 &plusmn; 2.7</strong></p></td><td><p dir="ltr"><strong>8.0 &plusmn; 2.4</strong></p></td></tr><tr><td><p dir="ltr"><strong>Clearance (l/h)</strong></p></td><td><p dir="ltr"><strong>12.7 &plusmn; 4.5</strong></p></td><td><p dir="ltr"><strong>1.25 &plusmn; 0.473</strong></p></td><td><p dir="ltr"><strong>2.5 &plusmn; 2.4</strong></p></td><td><p dir="ltr"><strong>4.5 &plusmn; 2.9</strong></p></td><td><p dir="ltr"><strong>6.4 &plusmn; 2.9</strong></p></td></tr><tr><td><p dir="ltr"><strong>t1/2 (h)</strong></p></td><td><p dir="ltr"><strong>6.5 &plusmn; 1.4</strong></p></td><td><p dir="ltr"><strong>1.97 &plusmn; 0.185</strong></p></td><td><p dir="ltr"><strong>3.1 &plusmn;1.4</strong></p></td><td><p dir="ltr"><strong>4.1 &plusmn; 1.3</strong></p></td><td><p dir="ltr"><strong>5.5 &plusmn; 1.1</strong></p></td></tr></tbody></table><p dir="ltr"><strong>* Extracted from study report PV 16000</strong></p><p>&nbsp;</p><p dir="ltr"><strong>The once daily dose of Valcyte in both of the studies described above was based on body surface area (BSA) and creatinine clearance (CrCl) derived from a modified Schwartz formula, and was calculated using the dosing algorithm presented in section 4.2.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Ganciclovir pharmacokinetics following valganciclovir administration were also evaluated in two studies in neonates and infants with symptomatic congenital CMV disease.&nbsp; In the first study 24 neonates aged 8 to 34 days received 6 mg/kg intravenous ganciclovir twice daily. Patients were then treated with oral valganciclovir, where the dose of valganciclovir powder for oral solution ranged from 14&nbsp;mg/kg to 20&nbsp;mg/kg twice daily; total treatment duration was 6 weeks.&nbsp; A dose of 16 mg/kg twice daily of valganciclovir powder for oral solution provided comparable ganciclovir exposure as 6 mg/kg intravenous ganciclovir twice daily in neonates, and also achieved ganciclovir exposure similar to the effective adult 5&nbsp;mg/kg intravenous dose.&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>In the second study, 109 neonates aged 2 to 30 days received 16 mg/kg valganciclovir powder for oral solution twice daily for 6 weeks and subsequently 96 out of 109 enrolled patients were randomized to continue receiving valganciclovir or placebo for 6 months. However, the mean AUC0-12h was lower compared to the mean AUC0-12h values from the first study.&nbsp; The following table shows the mean values of AUC, Cmax, and t&frac12; including standard deviations compared with adult data:</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>PK Parameter</strong></p></td><td><p dir="ltr"><strong>Adults</strong></p></td><td colspan="3"><p dir="ltr"><strong>Paediatrics (neonates and infants)</strong></p></td></tr><tr><td>&nbsp;</td><td><p dir="ltr"><strong>5 mg/kg GAN</strong></p><p dir="ltr"><strong>Single dose</strong></p><p dir="ltr"><strong>(n=8)</strong></p></td><td><p dir="ltr"><strong>6 mg/kg GAN</strong></p><p dir="ltr"><strong>Twice daily<br />(n=19)</strong></p></td><td><p dir="ltr"><strong>16 mg/kg VAL</strong></p><p dir="ltr"><strong>Twice daily</strong></p><p dir="ltr"><strong>(n=19)</strong></p></td><td><p dir="ltr"><strong>16 mg/kg VAL</strong></p><p dir="ltr"><strong>Twice daily</strong></p><p dir="ltr"><strong>(n = 100)</strong></p></td></tr><tr><td><p dir="ltr"><strong>AUC0-&infin; (&mu;g.h/mL)</strong></p></td><td><p dir="ltr"><strong>25.4 &plusmn; 4.32</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>AUC0-12h (&mu;g.h/mL)</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td><td><p dir="ltr"><strong>38.2 &plusmn; 42.7</strong></p></td><td><p dir="ltr"><strong>30.1 &plusmn; 15.1</strong></p></td><td><p dir="ltr"><strong>20.85 &plusmn; 5.40</strong></p></td></tr><tr><td><p dir="ltr"><strong>Cmax (&mu;g/ml)</strong></p></td><td><p dir="ltr"><strong>9.03 &plusmn; 1.26</strong></p></td><td><p dir="ltr"><strong>12.9 &plusmn; 21.5</strong></p></td><td><p dir="ltr"><strong>5.44&nbsp; &plusmn; 4. 04</strong></p></td><td><p dir="ltr"><strong>-</strong></p></td></tr><tr><td><p dir="ltr"><strong>t1/2 (h)</strong></p></td><td><p dir="ltr"><strong>3.32&nbsp; &plusmn; 0.47</strong></p></td><td><p dir="ltr"><strong>2.52 &plusmn; 0. 55</strong></p></td><td><p dir="ltr"><strong>2.98 &plusmn; 1. 26</strong></p></td><td><p dir="ltr"><strong>2.98 &plusmn; 1.12</strong></p></td></tr></tbody></table><p dir="ltr"><strong>GAN = Ganciclovir, i.v. VAL = Valganciclovir, oral&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>These data are too limited to allow conclusions regarding efficacy or posology recommendations for paediatric patients with congenital CMV infection.</strong></p><p><br /><br />&nbsp;</p><p dir="ltr"><strong>Elderly</strong></p><p dir="ltr"><strong>No investigations on valganciclovir or ganciclovir pharmacokinetics in adults older than 65 years of age have been undertaken (see section 4.2).</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with renal impairment</strong></p><p dir="ltr"><strong>The pharmacokinetics of ganciclovir from a single oral dose of 900 mg valganciclovir was evaluated in 24 otherwise healthy individuals with renal impairment.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pharmacokinetic parameters of ganciclovir from a single oral dose of 900 mg Valcyte tablets in patients with various degrees of renal impairment:</strong></p><p>&nbsp;</p><table><tbody><tr><td><p dir="ltr"><strong>Estimated Creatinine Clearance (mL/min)</strong></p></td><td><p dir="ltr"><strong>N</strong></p></td><td><p dir="ltr"><strong>Apparent Clearance (mL/min) Mean &plusmn; SD&nbsp;</strong></p></td><td><p dir="ltr"><strong>AUClast (&mu;g∙h/mL) Mean &plusmn; SD</strong></p></td><td><p dir="ltr"><strong>Half-life (hours) Mean &plusmn; SD</strong></p></td></tr><tr><td><p dir="ltr"><strong>51-70&nbsp;</strong></p></td><td><p dir="ltr"><strong>6&nbsp;</strong></p></td><td><p dir="ltr"><strong>249 &plusmn; 99&nbsp;</strong></p></td><td><p dir="ltr"><strong>49.5 &plusmn; 22.4&nbsp;</strong></p></td><td><p dir="ltr"><strong>4.85 &plusmn; 1.4&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>21-50&nbsp;</strong></p></td><td><p dir="ltr"><strong>6&nbsp;</strong></p></td><td><p dir="ltr"><strong>136 &plusmn; 64&nbsp;</strong></p></td><td><p dir="ltr"><strong>91.9 &plusmn; 43.9&nbsp;</strong></p></td><td><p dir="ltr"><strong>10.2 &plusmn; 4.4&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>11-20&nbsp;</strong></p></td><td><p dir="ltr"><strong>6&nbsp;</strong></p></td><td><p dir="ltr"><strong>45 &plusmn; 11&nbsp;</strong></p></td><td><p dir="ltr"><strong>223 &plusmn; 46&nbsp;</strong></p></td><td><p dir="ltr"><strong>21.8 &plusmn; 5.2&nbsp;</strong></p></td></tr><tr><td><p dir="ltr"><strong>&le;10&nbsp;</strong></p></td><td><p dir="ltr"><strong>6&nbsp;</strong></p></td><td><p dir="ltr"><strong>12.8 &plusmn; 8&nbsp;</strong></p></td><td><p dir="ltr"><strong>366 &plusmn; 66&nbsp;</strong></p></td><td><p dir="ltr"><strong>67.5 &plusmn; 34&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p><p dir="ltr"><strong>Decreasing renal function resulted in decreased clearance of ganciclovir from valganciclovir with a corresponding increase in terminal half-life. Therefore, dosage adjustment is required for renally impaired patients (see sections 4.2 and 4.4).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients undergoing haemodialysis&nbsp;</strong></p><p dir="ltr"><strong>For patients receiving haemodialysis dose recommendations for Valcyte 450&nbsp;mg film-coated tablets cannot be given.&nbsp; This is because an individual dose of Valcyte required for these patients is less than the 450&nbsp;mg tablet strength. Thus, Valcyte film-coated tablets should not be used in these patients (see sections 4.2 and 4.4).&nbsp;</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Stable liver transplant patients</strong></p><p dir="ltr"><strong>The pharmacokinetics of ganciclovir from valganciclovir in stable liver transplant patients were investigated in one open label 4-part crossover study (N=28). The bioavailability of ganciclovir from valganciclovir, following a single dose of 900 mg valganciclovir under fed conditions, was approximately 60%. Ganciclovir AUC0-24h was comparable to that achieved by 5 mg/kg intravenous ganciclovir in liver transplant patients.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with hepatic impairment</strong></p><p dir="ltr"><strong>The safety and efficacy of Valcyte film-coated tablets have not been studied in patients with hepatic impairment. Hepatic impairment should not affect the pharmacokinetics of ganciclovir since it is excreted renally and, therefore, no specific dose recommendation is made.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Patients with cystic fibrosis</strong></p><p dir="ltr"><strong>In a phase I pharmacokinetic study in lung transplant recipients with or without cystic fibrosis (CF), 31 patients (16 CF/15 non-CF) received post-transplant prophylaxis with 900 mg/day Valcyte.&nbsp; The study indicated that cystic fibrosis had no statistically significant influence on the overall average systemic exposure to ganciclovir in lung transplant recipients. Ganciclovir exposure in lung transplant recipients was comparable to that shown to be efficacious in the prevention of CMV disease in other solid organ transplant recipients.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Valganciclovir is a pro-drug of ganciclovir and therefore effects observed with ganciclovir apply equally to valganciclovir. Toxicity of valganciclovir in pre-clinical safety studies was the same as that seen with ganciclovir and was induced at ganciclovir exposure levels comparable to, or lower than, those in humans given the induction dose.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>These findings were gonadotoxicity (testicular cell loss) and nephrotoxicity (uraemia, cell degeneration), which were irreversible; myelotoxicity (anaemia, neutropenia, lymphocytopenia) and gastrointestinal toxicity (mucosal cell necrosis), which were reversible.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Ganciclovir was mutagenic in mouse lymphoma cells and clastogenic in mammalian cells. Such results are consistent with the positive mouse carcinogenicity study with ganciclovir. Ganciclovir is a potential carcinogen.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Further studies have shown ganciclovir to be teratogenic, embryotoxic, to inhibit spermatogenesis (i.e. impair male fertility) and to suppress female fertility.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Animal data indicate that ganciclovir is excreted in the milk of lactating rats.</strong></p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Tablet core Tablet film-coat</strong></p><p dir="ltr"><strong>Povidone K30 Opadry Pink 15B24005 containing:</strong></p><p dir="ltr"><strong>Crospovidone Hypromellose</strong></p><p dir="ltr"><strong>Microcrystalline cellulose Titanium dioxide (E171)</strong></p><p dir="ltr"><strong>Stearic acid Macrogol 400</strong></p><p dir="ltr"><strong>Red iron oxide (E172)</strong></p><p dir="ltr"><strong>Polysorbate 80</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><br /></p><p dir="ltr"><strong>Not applicable.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Do not store above 30&deg;C.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>High density polyethylene (HDPE) bottle, with child-resistant polypropylene closure, and cotton pad enclosed.</strong></p><p>&nbsp;</p><p dir="ltr"><strong>Pack size: One bottle containing 60 tablets.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124,
CH-4070 Basel,
Switzerland.
8.	MARKETING AUTHORISATION NUMBER(S) 

259-24-06


9.	DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

09 October 2006.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                16 May 2018.

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>